<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">DIJ</journal-id>
         <journal-id journal-id-type="hwp">spdij</journal-id>
         <journal-title>Drug Information Journal</journal-title>
         <issn pub-type="ppub">0092-8615</issn>
         <publisher>
            <publisher-name>SAGE Publications</publisher-name>
            <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.1177/0092861511427871</article-id>
         <article-id pub-id-type="publisher-id">10.1177_0092861511427871</article-id>
         <article-categories>
            <subj-group subj-group-type="heading">
               <subject>Student Papers</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>The Electronic Common Technical Document (eCTD)</article-title>
            <subtitle>An International Pro/Con Analysis of the Pharmaceutical Product Electronic Submission Process</subtitle>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" corresp="yes" xlink:type="simple">
               <name name-style="western">
                  <surname>Suchanek</surname>
                  <given-names>Andreas</given-names>
               </name>
               <xref ref-type="aff" rid="aff1-0092861511427871">1</xref>
               <xref ref-type="aff" rid="aff2-0092861511427871">2</xref>
               <xref ref-type="corresp" rid="corresp1-0092861511427871"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Ostermann</surname>
                  <given-names>Herwig</given-names>
               </name>
               <degrees>Prof., PhD</degrees>
               <xref ref-type="aff" rid="aff3-0092861511427871">3</xref>
            </contrib>
         </contrib-group>
         <aff id="aff1-0092861511427871">
            <label>1</label>Department of Human and Economic Sciences, UMIT—The Health &amp; Life Sciences University, Hall/Tyrol, Austria</aff>
         <aff id="aff2-0092861511427871">
            <label>2</label>Ascapex GmbH, Jetzendorf, Germany</aff>
         <aff id="aff3-0092861511427871">
            <label>3</label>Department of Public Health and Health Technology Assessment, UMIT—The Health &amp; Life Sciences University, Hall/Tyrol, Austria</aff>
         <author-notes>
            <corresp id="corresp1-0092861511427871">Andreas Suchanek, UMIT—The Health &amp; Life Sciences University, Hall/Tyrol, Austria (email: <email xlink:type="simple">andreas.suchanek@umit.at</email> or <email xlink:type="simple">suchanek@ascapex.com</email>).</corresp>
         </author-notes>
         <pub-date pub-type="epub-ppub">
            <month>1</month>
            <year>2012</year>
         </pub-date>
         <volume>46</volume>
         <issue>1</issue>
         <fpage>124</fpage>
         <lpage>139</lpage>
         <history>
            <date date-type="received">
               <day>30</day>
               <month>6</month>
               <year>2011</year>
            </date>
            <date date-type="accepted">
               <day>22</day>
               <month>8</month>
               <year>2011</year>
            </date>
         </history>
         <permissions>
            <copyright-statement>© Drug Information Association 2012</copyright-statement>
            <copyright-year>2012</copyright-year>
            <copyright-holder content-type="society">Drug Information Association</copyright-holder>
         </permissions>
         <abstract>
            <p>The International Conference on Harmonisation’s electronic Common Technical Document (eCTD) endeavors to significantly change the pharmaceutical submission process. After decades of using paper, the goal is the electronic transfer of drug applications and their review across submission formats, procedures, and regions. However, it is still unclear whether implementing eCTD really brings more advantages than disadvantages and, if so, for what kind of companies. After an expert interview was conducted in 2009, this research study was formed as an international survey officially supported by the European Medicines Agency in 2010. Overall, 963 responses were received, and 397 were used for the subsequent study analysis. Although a three-fourths majority of those with eCTD experience reported disadvantages in implementing eCTD, an overwhelming majority of the same group reported advantages that outweighed the disadvantages, some of them significantly. More than three-quarters of individuals with eCTD experience were able to shorten their total time to approval, and more than 90% of this group was able to demonstrate cost savings relative to paper submissions, regardless of their company kind, size, or number of submissions.</p>
         </abstract>
         <kwd-group>
            <kwd>electronic Common Technical Document (eCTD)/(CTD)</kwd>
            <kwd>drug regulatory affairs</kwd>
            <kwd>drug registration process</kwd>
            <kwd>eCTD advantages and disadvantages</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="section1-0092861511427871">
         <title>Introduction</title>
         <p>For several decades, paper-based submissions have been the method of choice for the drug registration process in the pharmaceutical industry. However, changing information technology trends, the extensiveness of data, consistently decreasing reviewing times, and nearly nonexistent paper archiving capacities at regulatory authorities’ facilities make electronic-only submissions necessary.<sup>
               <xref ref-type="bibr" rid="bibr1-0092861511427871">1</xref>,<xref ref-type="bibr" rid="bibr2-0092861511427871">2</xref>
            </sup>
         </p>
         <p>The electronic Common Technical Document (eCTD)<sup>
               <xref ref-type="bibr" rid="bibr3-0092861511427871">3</xref>
            </sup> has been defined by the European Medicines Agency (EMA) in this manner: “an eCTD is the submission of (mostly) PDF leaf documents, stored in the eCTD directory structure, crucially accessed through the XML backbone (index.xml) and with the files’ integrity guaranteed by the MD5 Checksum.”<sup>
               <xref ref-type="bibr" rid="bibr4-0092861511427871">4</xref>
            </sup> It is more succinctly described as the defined electronic transfer format of the paper-based CTD, and it strives to become the most important pharmaceutical electronic submission format. Nonetheless, after 8 years of being defined through the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH),<sup>
               <xref ref-type="bibr" rid="bibr3-0092861511427871">3</xref>,<xref ref-type="bibr" rid="bibr5-0092861511427871">5</xref>
            </sup> discussions of its use generate more questions than answers in the industry.</p>
         <p>“However, there are immense value and benefits of ICH to regulators as well. The CTD and the eCTD have revolutionized how submissions are reviewed. They have created a common regulatory language that promotes good document review practices and ultimately leads to faster access to life-saving medicines, even beyond the ICH regions.”<sup>
               <xref ref-type="bibr" rid="bibr6-0092861511427871">6</xref>
            </sup> The eCTD not only aims to facilitate the data transfer (receipt and processing) and review process but also helps in reducing physical paper flow and in the storage of regulatory submissions and their related life cycle management.<sup>
               <xref ref-type="bibr" rid="bibr5-0092861511427871">5</xref>,<xref ref-type="bibr" rid="bibr7-0092861511427871">7</xref>
               <xref ref-type="bibr" rid="bibr8-0092861511427871"/>–<xref ref-type="bibr" rid="bibr9-0092861511427871">9</xref>
            </sup>
         </p>
         <p>In addition, it must be noted that the eCTD conversely is not a regulatory reviewing system, has no single implementation and interpretation across worldwide regions, and has no scientific content definition nor is it a simple electronic set of PDF files and folders.<sup>
               <xref ref-type="bibr" rid="bibr10-0092861511427871">10</xref>
            </sup>
         </p>
         <p>During the past few years, one can note an increased trend toward global drug regulatory harmonization (eg, Asia-Pacific Economic Cooperation [APEC], Association of the Southeast Asian Nations [ASEAN], Gulf Cooperation Council [GCC]),<sup>
               <xref ref-type="bibr" rid="bibr11-0092861511427871">11</xref>,<xref ref-type="bibr" rid="bibr12-0092861511427871">12</xref>
            </sup> along with further CTD/eCTD expansion to non-ICH regions.<sup>
               <xref ref-type="bibr" rid="bibr13-0092861511427871">13</xref>,<xref ref-type="bibr" rid="bibr14-0092861511427871">14</xref>
            </sup>
         </p>
         <p>Electronic submissions, especially eCTDs, not only evoke a lot of general advantages<sup>
               <xref ref-type="bibr" rid="bibr15-0092861511427871">15</xref>
            </sup> for industry and regulators but can also improve the whole drug registration process for all pharmaceutical products from premarketing evaluation through marketing authorization to postmarketing review.<sup>
               <xref ref-type="bibr" rid="bibr16-0092861511427871">16</xref>,<xref ref-type="bibr" rid="bibr17-0092861511427871">17</xref>
            </sup>
         </p>
         <p>Because paper handling is expensive<sup>
               <xref ref-type="bibr" rid="bibr18-0092861511427871">18</xref>
            </sup> and associated with additional problems such as absence of suitable archive storage, its appropriate reduction is critical and made possible by using eCTD. For non-eCTD electronic submissions (NEESs), however, the benefit is less clear,<sup>
               <xref ref-type="bibr" rid="bibr2-0092861511427871">2</xref>,<xref ref-type="bibr" rid="bibr19-0092861511427871">19</xref>
            </sup> and electronic submissions without any regulatory authority technical standard definition alone are unlikely to be equally effective.<sup>
               <xref ref-type="bibr" rid="bibr20-0092861511427871">20</xref>
            </sup>
         </p>
         <p>Therefore, an eCTD-only acceptance by regulatory authorities was advanced, and the usage of eCTDs has been more strongly recommended.<sup>
               <xref ref-type="bibr" rid="bibr21-0092861511427871">21</xref>,<xref ref-type="bibr" rid="bibr22-0092861511427871">22</xref>
            </sup> Some agencies have already made eCTD their mandatory submission format for electronic submissions,<sup>
               <xref ref-type="bibr" rid="bibr23-0092861511427871">23</xref>
            </sup> and others are working to make it completely mandatory during the next few years.<sup>
               <xref ref-type="bibr" rid="bibr24-0092861511427871">24</xref>
            </sup>
         </p>
         <p>That said, the eCTD still does not have full industry acceptance. It is the sixth electronic submission standard worldwide since 1994 (not yet 20 years ago),<sup>
               <xref ref-type="bibr" rid="bibr25-0092861511427871">25</xref>
            </sup> it still has a chance of failure,<sup>
               <xref ref-type="bibr" rid="bibr26-0092861511427871">26</xref>,<xref ref-type="bibr" rid="bibr27-0092861511427871">27</xref>
            </sup> and the ICH and other standard bodies (eg, HL7) are already working on the next major version of it (regulated product submission [RPS]; eCTD next major version [NMV]; eCTD 4.0).<sup>
               <xref ref-type="bibr" rid="bibr28-0092861511427871">28</xref>,<xref ref-type="bibr" rid="bibr29-0092861511427871">29</xref>
            </sup>
         </p>
         <p>Roughly 40% of all investigational new drug applications (INDs; 36,814 of 92,218) and around 62% of all new drug applications (NDAs; 14,007 of 22,443) to the US Food and Drug Administration (FDA) in January to October 2010 were eCTD submissions,<sup>
               <xref ref-type="bibr" rid="bibr30-0092861511427871">30</xref>
            </sup> but only 7% of all application filings in Europe in 2009 were eCTD submissions (29,954 of 219,537 application filings across formats and procedures).<sup>
               <xref ref-type="bibr" rid="bibr31-0092861511427871">31</xref>
            </sup> And in Japan, the percentage is also very small, with only 207 eCTDs having been received between 2004 and 2010.<sup>
               <xref ref-type="bibr" rid="bibr32-0092861511427871">32</xref>
            </sup>
         </p>
         <p>Although they can offer considerable advantages, eCTD solutions can be an expensive purchase. They can also entail several disadvantages and may interrupt the day-to-day business of a company. It is also not easy to find appropriate staff to consult, implement, and maintain a whole eCTD infrastructure.<sup>
               <xref ref-type="bibr" rid="bibr33-0092861511427871">33</xref>
            </sup>
         </p>
         <p>Existing studies in this field are limited in their ability to accurately provide quantitative data on eCTD advantages and disadvantages and how these advantages and disadvantages compare. They also fail in identifying company variables influencing these advantages and disadvantages. Consequently, the objective of this study was to compare measureable eCTD advantages and disadvantages, variables influencing them, and a potential improvement in time to approval for pharmaceutical medicine provided by the most current practice of paper-based CTD submissions.</p>
      </sec>
      <sec id="section2-0092861511427871">
         <title>Methods</title>
         <p>The study design was divided into 2 parts. The first part, an expert interview in the style of the Delphi method involving 8 international eCTD experts, was published in the third quarter of 2009, thus forming the qualitative deductive part. Subsequently, the answers were grouped in 2 categories (advantages and disadvantages) and thus built the basis for this quantitative inductive part.<sup>
               <xref ref-type="bibr" rid="bibr15-0092861511427871">15</xref>
            </sup>
         </p>
         <p>The second research part started with the creation of a survey including 26 closed-ended questions in 4 categories. Questions 1 to 12, representing category 1 (the descriptive component), were classification questions based on the year 2009. Then, the part on eCTD disadvantages comprised 7 questions (13-19), and the part on eCTD advantages comprised 8 questions (20-25 [question 20 is divided into 3 subquestions]). Finally, question 26 asked for the percentage savings in time to market/approval due to the new eCTD-based submission approach. These questions are provided in <xref ref-type="table" rid="table1-0092861511427871">Table 1</xref>.</p>
         <table-wrap id="table1-0092861511427871" position="float">
            <label>Table 1.</label>
            <caption>
               <p>Online Survey Questions</p>
            </caption>
            <graphic alt-version="no" alternate-form-of="table1-0092861511427871" position="float" xlink:href="10.1177_0092861511427871-table1.tif" xlink:type="simple"/>
            <table>
               <tbody>
                  <tr>
                     <td colspan="1" rowspan="1">Category 1 Questions 1-12: Classification Questions</td>
                     <td align="left" colspan="1" rowspan="1">Category 2 Questions 13-19: eCTD Disadvantages</td>
                     <td align="left" colspan="1" rowspan="1">Category 3 Questions 20-26: eCTD Advantages</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1"> 1. What kind of pharmaceutical company do you work for?<break/> 2. Do you work for a subsidiary/division of an international pharmaceutical company or for the parent company?<break/> 3. In what country are you employed?<break/> 4. What is your company’s annual revenue in US dollars?<break/> 5. Does your pharmaceutical company/group have a chief information officer (CIO)?<break/> 6. How many drug products does your company manage?<break/> 7. How many submissions does your company manage per year?<break/> 8. How many employees were working in the regulatory affairs department?<break/> 9. How many external staff were working in regulatory affairs?<break/>10. How many employees were working in your corporate IT department?<break/>11. How many external staff support your IT department?<break/>12. Has your company submitted one or more eCTD sequences for review by a regulatory authority in North America or Europe yet?</td>
                     <td colspan="1" rowspan="1">13. What was the cost of your new eCTD tool, including new hardware training, etc?<break/>14. What was your migration cost from an old e-submission tool to the new eCTD tool, if any?<break/>15. What was your % loss of time impact on your submission process due the difference of interpretation of the eCTD standard by different regulatory authorities, compared with paper-based submissions?<break/>16. What was your % loss of time due to the need to render PDF documents and setting of bookmarks and/or hyperlinks for eCTD submissions compared with paper-based submissions?<break/>17. What was your % loss of time because of the necessity for implementing new electronic-supported eCTD processes compared with paper-based submissions?<break/>18. What was your % loss of time because of a lack of eCTD qualified people compared with paper-based submissions?<break/>19. What percentage of your initial eCTD investment did you have to spend for additional IT and electronic archival costs per year?</td>
                     <td colspan="1" rowspan="1">20. What was your % savings in paper costs for: printing? handling/logistics? archiving?<break/>21. What is your % savings in time for submission life cycle support, compared with paper-based submissions?<break/>22. What is your % savings in time due to new eCTD-based processes compared with paper-based submissions?<break/>23. What is your % savings in time due to new eCTD-based searchable/findable content and metadata and their reuse compared with paper-based submissions?<break/>24. What is your % savings in time due to new eCTD-supported transfer possibilities compared with paper-based submissions?<break/>25. What is your % savings in time due to new eCTD-supported dossier navigation and review possibilities compared with paper-based submissions?<break/>26. What was your % savings in time to market/approval with an eCTD-based approach compared to a paper-based approach? (0% = no improvement)</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">
</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <fn id="table-fn1-0092861511427871">
                  <p>eCTD, electronic Common Technical Document; IT, information technology.</p>
               </fn>
            </table-wrap-foot>
         </table-wrap>
         <p>All dependent variables, except direct cost variables such as implementation and training costs, migration costs, and additional information technology (IT) and electronic archival costs, had the same 8-level scale—0%, &lt;10%, 10% to &lt;20%, 20% to &lt;30%, 30% to &lt;40%, ∼50%, &gt;50% to &lt;75%, and ≥75%—in time loss (ie, improvement) through the eCTD-based approach in comparison to the paper-based CTD approach. Such similar arrangement was necessary to allow for a better comparison and analysis among each other and to stay valid and consistent for all kinds of answering companies (eg, Big Pharma vs small service organization).</p>
         <p>Answers to question 3 (“In what country are you employed?”) were grouped the following way: the United States remained territory “U.S.A.”; Austria, Belgium, Cyprus, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Malta, Netherlands, Poland, Romania, Spain, Sweden, and the United Kingdom were assembled into the territory “Europe”; and Canada plus “Other” were defined as the “rest of the world” (RoW). Although Japan was 1 of the 3 founding members of the ICH,<sup>
               <xref ref-type="bibr" rid="bibr34-0092861511427871">34</xref>
            </sup> it has had very little eCTD so far<sup>
               <xref ref-type="bibr" rid="bibr32-0092861511427871">32</xref>
            </sup> and received the pick list possibility of “Other.”</p>
         <p>After finalizing the questionnaire, the password-protected survey went online for a pretest period of 2 weeks. Ten dedicated drug regulatory affairs (DRA) experts (the 8 experts of the part 1 expert interview, plus 2 new experts) were asked to work through the survey and propose potential changes. Several suggested changes had been implemented into the survey before going online.</p>
         <p>Subsequent to the conclusion of the pretest period, the survey went live, and the e-mail invitation to participate, officially supported by the EMA plus more than 50 associations, vendors, and individuals, was sent to more than 22,000 regulatory affairs people in pharmaceutical/biotech/generic companies or service providers.</p>
         <p>The most used contact database had the following fragmentation: regulatory affairs people worldwide: 22,056, with North America (10,428; 47%), Europe (8807; 40%), and RoW (2821; 13%) contacts representing 9106 companies. The size of companies was partitioned into 2987 companies with less than US$500 million revenue and 6119 companies with more than US$500 million revenue. Fifty-five percent of the companies were pharmaceutical and biotech companies (43% pharmaceutical + 12% biotech), 37% were generic companies, and 8% were service providers (total = 100%).</p>
         <p>The survey stayed online for 90 days and was analyzed between November 2010 and May 2011.</p>
         <p>All statistical analyses were performed with the use of PASW Statistics version 17 (formerly SPSS, Inc, an IBM Company, Chicago, Illinois) and Microsoft Excel version 14 (Microsoft, Redmond, Washington). A 2-sided Pearson χ<sup>2</sup> value (<italic>P </italic>value) of less than .05 was considered to indicate statistical significance.</p>
      </sec>
      <sec id="section3-0092861511427871">
         <title>Results</title>
         <p>From June 26, 2010, to September 23, 2010, a total of 963 cases were created through the described online survey. Of the total 963 people who logged on, 297 cases did not answer any question of the survey, and 216 cases were not completely finished. Another 23 cases were unusable because of their noncompatibility to scientific data quality standards. The remaining data set of 427 cases was split into 2 groups: “eCTD experience—existing” or “eCTD experience—not existing.” Of the 427 cases, 319 already had “submitted one or more eCTD sequences for review by a regulatory authority” (question 12), and 108 did not. The latter used this online survey as a platform to express their estimates for potential eCTD disadvantages and advantages. Of the 319 cases, 30 also were rejected because they did not answer the “time to approval” (T2A) question (question 26), which left a total of 289 cases for the subsequent sample set “eCTD experience—existing” (<xref ref-type="fig" rid="fig1-0092861511427871">Figure 1</xref>).</p>
         <fig id="fig1-0092861511427871" position="float">
            <label>Figure 1.</label>
            <caption>
               <p>Case funnel.</p>
            </caption>
            <graphic alt-version="no" alternate-form-of="fig1-0092861511427871" position="float" xlink:href="10.1177_0092861511427871-fig1.tif" xlink:type="simple"/>
         </fig>
         <p>The differentiation between existing eCTD experience and missing eCTD experience indicated the following: the bigger the represented company, the greater the number of products/number of submissions, and the more people in internal regulatory affairs and internal and external IT, the more eCTD experience. However, such correlation could not be made with respect to the number of external regulatory people.</p>
         <p>For some parts of the subsequent study analysis, the cases in the “eCTD experience—existing” group (n = 289) were also allocated into 3 subgroups: group 1 (answering value “1”), including 66 cases, equivalent to 23% of the total, observed no improvement in time to approval through eCTD (T2A) in comparison to the previous paper-based submission process. Group 2 (answering values “2,” “3,” “4,” and “5”), including 164 cases (57%), had a related T2A improvement of up to 40%. Group 3 (answering values “6,” “7,” and “8”), including 59 cases or 20% of the total, improved T2A by 50% and more (<xref ref-type="fig" rid="fig2-0092861511427871">Figure 2</xref>).</p>
         <fig id="fig2-0092861511427871" position="float">
            <label>Figure 2.</label>
            <caption>
               <p>Electronic Common Technical Document (eCTD) experience existing—case classification.</p>
            </caption>
            <graphic alt-version="no" alternate-form-of="fig2-0092861511427871" position="float" xlink:href="10.1177_0092861511427871-fig2.tif" xlink:type="simple"/>
         </fig>
         <sec id="section4-0092861511427871">
            <title>Baseline Characteristics</title>
            <p>
               <xref ref-type="table" rid="table2-0092861511427871">Table 2</xref> provides a summary of the descriptive independent questions 1 to 11 and variables of the survey, divided into the above-mentioned group 1 (no improvement in time to approval), group 2 (improvement in time to approval &lt;40%), and group 3 (improvement in time to approval ≥50%) and their statistical 2-sided Pearson χ<sup>2</sup> values (<italic>P</italic> value).</p>
            <table-wrap id="table2-0092861511427871" position="float">
               <label>Table 2.</label>
               <caption>
                  <p>Baseline Characteristics</p>
               </caption>
               <graphic alt-version="no" alternate-form-of="table2-0092861511427871" position="float" xlink:href="10.1177_0092861511427871-table2.tif" xlink:type="simple"/>
               <graphic alt-version="no" alternate-form-of="table2-0092861511427871" position="float" xlink:href="10.1177_0092861511427871-table2a.tif" xlink:type="simple"/>
               <table>
                  <thead>
                     <tr>
                        <th colspan="1" rowspan="1"> </th>
                        <th colspan="4" rowspan="1">Group 1: No Improvement in Time to Approval (n = 66/22.8% of Total)</th>
                        <th colspan="4" rowspan="1">Group 2: Improvement in Time to Approval &lt;40% (n = 164/56.8% of Total)</th>
                        <th colspan="4" rowspan="1">Group 3: Improvement in Time to Approval &gt;50% (n = 59/20.4% of Total)</th>
                        <th colspan="3" rowspan="1">Total (n = 289/100% of Total)</th>
                     </tr>
                     <tr>
                        <th colspan="1" rowspan="1">
</th>
                        <th colspan="1" rowspan="1">No. in Group</th>
                        <th colspan="1" rowspan="1">% of Group</th>
                        <th colspan="1" rowspan="1">% Line-Item</th>
                        <th colspan="1" rowspan="1">% of Total</th>
                        <th colspan="1" rowspan="1">No. in Group</th>
                        <th colspan="1" rowspan="1">% of Group</th>
                        <th colspan="1" rowspan="1">% Line-Item</th>
                        <th colspan="1" rowspan="1">% of Total</th>
                        <th colspan="1" rowspan="1">No. in Group</th>
                        <th colspan="1" rowspan="1">% of Group</th>
                        <th colspan="1" rowspan="1">% Line-Item</th>
                        <th colspan="1" rowspan="1">% of Total</th>
                        <th colspan="1" rowspan="1">Total No.</th>
                        <th colspan="1" rowspan="1">% of Total</th>
                        <th colspan="1" rowspan="1">
                           <italic>P</italic> Value</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td colspan="1" rowspan="1">Location</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Europe (n = 112)</td>
                        <td colspan="1" rowspan="1">40</td>
                        <td colspan="1" rowspan="1">60.6</td>
                        <td colspan="1" rowspan="1">35.7</td>
                        <td colspan="1" rowspan="1">13.8</td>
                        <td colspan="1" rowspan="1">63</td>
                        <td colspan="1" rowspan="1">38.4</td>
                        <td colspan="1" rowspan="1">56.3</td>
                        <td colspan="1" rowspan="1">21.8</td>
                        <td colspan="1" rowspan="1">9</td>
                        <td colspan="1" rowspan="1">15.3</td>
                        <td colspan="1" rowspan="1">8.0</td>
                        <td colspan="1" rowspan="1">3.1</td>
                        <td colspan="1" rowspan="1">112</td>
                        <td colspan="1" rowspan="1">38.8</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Rest of world (n = 46)</td>
                        <td colspan="1" rowspan="1">8</td>
                        <td colspan="1" rowspan="1">12.1</td>
                        <td colspan="1" rowspan="1">17.4</td>
                        <td colspan="1" rowspan="1">2.8</td>
                        <td colspan="1" rowspan="1">26</td>
                        <td colspan="1" rowspan="1">15.9</td>
                        <td colspan="1" rowspan="1">56.5</td>
                        <td colspan="1" rowspan="1">9.0</td>
                        <td colspan="1" rowspan="1">12</td>
                        <td colspan="1" rowspan="1">20.3</td>
                        <td colspan="1" rowspan="1">26.1</td>
                        <td colspan="1" rowspan="1">4.2</td>
                        <td colspan="1" rowspan="1">46</td>
                        <td colspan="1" rowspan="1">15.9</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> North America (n = 131)</td>
                        <td colspan="1" rowspan="1">18</td>
                        <td colspan="1" rowspan="1">27.3</td>
                        <td colspan="1" rowspan="1">13.7</td>
                        <td colspan="1" rowspan="1">6.2</td>
                        <td colspan="1" rowspan="1">75</td>
                        <td colspan="1" rowspan="1">45.7</td>
                        <td colspan="1" rowspan="1">57.3</td>
                        <td colspan="1" rowspan="1">26.0</td>
                        <td colspan="1" rowspan="1">38</td>
                        <td colspan="1" rowspan="1">64.4</td>
                        <td colspan="1" rowspan="1">29.0</td>
                        <td colspan="1" rowspan="1">13.1</td>
                        <td colspan="1" rowspan="1">131</td>
                        <td colspan="1" rowspan="1">45.3</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Total</td>
                        <td colspan="1" rowspan="1">66</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">22.8</td>
                        <td colspan="1" rowspan="1">164</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">56.8</td>
                        <td colspan="1" rowspan="1">59</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">289</td>
                        <td colspan="1" rowspan="1">55.0</td>
                        <td colspan="1" rowspan="1">&lt;.001</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Kind of company<sup>
                              <xref ref-type="table-fn" rid="table-fn2-0092861511427871">a</xref>
                           </sup>
                        </td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Pharma/biotech (n = 226)</td>
                        <td colspan="1" rowspan="1">48</td>
                        <td colspan="1" rowspan="1">70.6</td>
                        <td colspan="1" rowspan="1">21.2</td>
                        <td colspan="1" rowspan="1">15.7</td>
                        <td colspan="1" rowspan="1">132</td>
                        <td colspan="1" rowspan="1">76.7</td>
                        <td colspan="1" rowspan="1">58.4</td>
                        <td colspan="1" rowspan="1">43.3</td>
                        <td colspan="1" rowspan="1">46</td>
                        <td colspan="1" rowspan="1">70.8</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">15.1</td>
                        <td colspan="1" rowspan="1">226</td>
                        <td colspan="1" rowspan="1">74.1</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Generic (n = 36)</td>
                        <td colspan="1" rowspan="1">8</td>
                        <td colspan="1" rowspan="1">11.8</td>
                        <td colspan="1" rowspan="1">22.2</td>
                        <td colspan="1" rowspan="1">2.6</td>
                        <td colspan="1" rowspan="1">19</td>
                        <td colspan="1" rowspan="1">11.0</td>
                        <td colspan="1" rowspan="1">52.8</td>
                        <td colspan="1" rowspan="1">6.2</td>
                        <td colspan="1" rowspan="1">9</td>
                        <td colspan="1" rowspan="1">13.8</td>
                        <td colspan="1" rowspan="1">25.0</td>
                        <td colspan="1" rowspan="1">3.0</td>
                        <td colspan="1" rowspan="1">36</td>
                        <td colspan="1" rowspan="1">11.8</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Service bureau (n = 43)</td>
                        <td colspan="1" rowspan="1">12</td>
                        <td colspan="1" rowspan="1">17.6</td>
                        <td colspan="1" rowspan="1">27.9</td>
                        <td colspan="1" rowspan="1">3.9</td>
                        <td colspan="1" rowspan="1">21</td>
                        <td colspan="1" rowspan="1">12.2</td>
                        <td colspan="1" rowspan="1">48.8</td>
                        <td colspan="1" rowspan="1">6.9</td>
                        <td colspan="1" rowspan="1">10</td>
                        <td colspan="1" rowspan="1">15.4</td>
                        <td colspan="1" rowspan="1">23.3</td>
                        <td colspan="1" rowspan="1">3.3</td>
                        <td colspan="1" rowspan="1">43</td>
                        <td colspan="1" rowspan="1">14.1</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">68</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">22.3</td>
                        <td colspan="1" rowspan="1">172</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">56.4</td>
                        <td colspan="1" rowspan="1">65</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">21.3</td>
                        <td colspan="1" rowspan="1">305</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">.946</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Headquarters (n = 217)</td>
                        <td colspan="1" rowspan="1">51</td>
                        <td colspan="1" rowspan="1">77.3</td>
                        <td colspan="1" rowspan="1">23.5</td>
                        <td colspan="1" rowspan="1">17.6</td>
                        <td colspan="1" rowspan="1">126</td>
                        <td colspan="1" rowspan="1">76.8</td>
                        <td colspan="1" rowspan="1">58.1</td>
                        <td colspan="1" rowspan="1">43.6</td>
                        <td colspan="1" rowspan="1">40</td>
                        <td colspan="1" rowspan="1">67.8</td>
                        <td colspan="1" rowspan="1">18.4</td>
                        <td colspan="1" rowspan="1">13.8</td>
                        <td colspan="1" rowspan="1">217</td>
                        <td colspan="1" rowspan="1">75.1</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Subsidiary (n = 66)</td>
                        <td colspan="1" rowspan="1">13</td>
                        <td colspan="1" rowspan="1">19.7</td>
                        <td colspan="1" rowspan="1">19.7</td>
                        <td colspan="1" rowspan="1">4.5</td>
                        <td colspan="1" rowspan="1">35</td>
                        <td colspan="1" rowspan="1">21.3</td>
                        <td colspan="1" rowspan="1">53.0</td>
                        <td colspan="1" rowspan="1">12.1</td>
                        <td colspan="1" rowspan="1">18</td>
                        <td colspan="1" rowspan="1">30.5</td>
                        <td colspan="1" rowspan="1">27.3</td>
                        <td colspan="1" rowspan="1">6.2</td>
                        <td colspan="1" rowspan="1">66</td>
                        <td colspan="1" rowspan="1">22.8</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> No answer (n = 6)</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">3.0</td>
                        <td colspan="1" rowspan="1">33.3</td>
                        <td colspan="1" rowspan="1">0.7</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">1.8</td>
                        <td colspan="1" rowspan="1">50.0</td>
                        <td colspan="1" rowspan="1">1.0</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">1.7</td>
                        <td colspan="1" rowspan="1">16.7</td>
                        <td colspan="1" rowspan="1">0.3</td>
                        <td colspan="1" rowspan="1">6</td>
                        <td colspan="1" rowspan="1">2.1</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Total</td>
                        <td colspan="1" rowspan="1">66</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">22.8</td>
                        <td colspan="1" rowspan="1">164</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">56.75</td>
                        <td colspan="1" rowspan="1">59</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">289</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">.290</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Company size</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Up to US$500 million (n = 120)</td>
                        <td colspan="1" rowspan="1">32</td>
                        <td colspan="1" rowspan="1">48.5</td>
                        <td colspan="1" rowspan="1">26.7</td>
                        <td colspan="1" rowspan="1">11.1</td>
                        <td colspan="1" rowspan="1">64</td>
                        <td colspan="1" rowspan="1">39.0</td>
                        <td colspan="1" rowspan="1">53.3</td>
                        <td colspan="1" rowspan="1">22.1</td>
                        <td colspan="1" rowspan="1">24</td>
                        <td colspan="1" rowspan="1">40.7</td>
                        <td colspan="1" rowspan="1">20.0</td>
                        <td colspan="1" rowspan="1">8.3</td>
                        <td colspan="1" rowspan="1">120</td>
                        <td colspan="1" rowspan="1">41.5</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Up to US$3 billion (n = 59)</td>
                        <td colspan="1" rowspan="1">8</td>
                        <td colspan="1" rowspan="1">12.1</td>
                        <td colspan="1" rowspan="1">13.6</td>
                        <td colspan="1" rowspan="1">2.8</td>
                        <td colspan="1" rowspan="1">40</td>
                        <td colspan="1" rowspan="1">24.4</td>
                        <td colspan="1" rowspan="1">67.8</td>
                        <td colspan="1" rowspan="1">13.8</td>
                        <td colspan="1" rowspan="1">11</td>
                        <td colspan="1" rowspan="1">18.6</td>
                        <td colspan="1" rowspan="1">18.6</td>
                        <td colspan="1" rowspan="1">3.8</td>
                        <td colspan="1" rowspan="1">59</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &gt;US$3 billion (n = 103)</td>
                        <td colspan="1" rowspan="1">26</td>
                        <td colspan="1" rowspan="1">39.4</td>
                        <td colspan="1" rowspan="1">25.2</td>
                        <td colspan="1" rowspan="1">9.0</td>
                        <td colspan="1" rowspan="1">54</td>
                        <td colspan="1" rowspan="1">32.9</td>
                        <td colspan="1" rowspan="1">52.4</td>
                        <td colspan="1" rowspan="1">18.7</td>
                        <td colspan="1" rowspan="1">23</td>
                        <td colspan="1" rowspan="1">39.0</td>
                        <td colspan="1" rowspan="1">22.3</td>
                        <td colspan="1" rowspan="1">8.0</td>
                        <td colspan="1" rowspan="1">103</td>
                        <td colspan="1" rowspan="1">35.6</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> No answer (n = 7)</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">6</td>
                        <td colspan="1" rowspan="1">3.7</td>
                        <td colspan="1" rowspan="1">85.7</td>
                        <td colspan="1" rowspan="1">2.1</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">1.7</td>
                        <td colspan="1" rowspan="1">14.3</td>
                        <td colspan="1" rowspan="1">0.3</td>
                        <td colspan="1" rowspan="1">7</td>
                        <td colspan="1" rowspan="1">2.4</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Total</td>
                        <td colspan="1" rowspan="1">66</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">22.8</td>
                        <td colspan="1" rowspan="1">164</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">56.75</td>
                        <td colspan="1" rowspan="1">59</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">289</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">.152</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Chief information officer</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Yes (n = 161)</td>
                        <td colspan="1" rowspan="1">38</td>
                        <td colspan="1" rowspan="1">57.6</td>
                        <td colspan="1" rowspan="1">23.6</td>
                        <td colspan="1" rowspan="1">13.1</td>
                        <td colspan="1" rowspan="1">95</td>
                        <td colspan="1" rowspan="1">57.9</td>
                        <td colspan="1" rowspan="1">59.0</td>
                        <td colspan="1" rowspan="1">32.9</td>
                        <td colspan="1" rowspan="1">28</td>
                        <td colspan="1" rowspan="1">47.5</td>
                        <td colspan="1" rowspan="1">17.4</td>
                        <td colspan="1" rowspan="1">9.7</td>
                        <td colspan="1" rowspan="1">161</td>
                        <td colspan="1" rowspan="1">55.7</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> No (n = 125)</td>
                        <td colspan="1" rowspan="1">28</td>
                        <td colspan="1" rowspan="1">42.4</td>
                        <td colspan="1" rowspan="1">22.4</td>
                        <td colspan="1" rowspan="1">9.7</td>
                        <td colspan="1" rowspan="1">68</td>
                        <td colspan="1" rowspan="1">41.5</td>
                        <td colspan="1" rowspan="1">54.4</td>
                        <td colspan="1" rowspan="1">23.5</td>
                        <td colspan="1" rowspan="1">29</td>
                        <td colspan="1" rowspan="1">49.2</td>
                        <td colspan="1" rowspan="1">23.2</td>
                        <td colspan="1" rowspan="1">10.0</td>
                        <td colspan="1" rowspan="1">125</td>
                        <td colspan="1" rowspan="1">43.3</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> No answer (n = 3)</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">0.6</td>
                        <td colspan="1" rowspan="1">33.3</td>
                        <td colspan="1" rowspan="1">0.3</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">3.4</td>
                        <td colspan="1" rowspan="1">66.7</td>
                        <td colspan="1" rowspan="1">0.7</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">1.0</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Total</td>
                        <td colspan="1" rowspan="1">66</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">22.8</td>
                        <td colspan="1" rowspan="1">164</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">56.75</td>
                        <td colspan="1" rowspan="1">59</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">289</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">.473</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">No. of products</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &lt;50 (n = 158)</td>
                        <td colspan="1" rowspan="1">39</td>
                        <td colspan="1" rowspan="1">59.1</td>
                        <td colspan="1" rowspan="1">24.7</td>
                        <td colspan="1" rowspan="1">13.5</td>
                        <td colspan="1" rowspan="1">86</td>
                        <td colspan="1" rowspan="1">52.4</td>
                        <td colspan="1" rowspan="1">54.4</td>
                        <td colspan="1" rowspan="1">29.8</td>
                        <td colspan="1" rowspan="1">33</td>
                        <td colspan="1" rowspan="1">55.9</td>
                        <td colspan="1" rowspan="1">20.9</td>
                        <td colspan="1" rowspan="1">11.4</td>
                        <td colspan="1" rowspan="1">158</td>
                        <td colspan="1" rowspan="1">54.7</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &lt;250 (n = 63)</td>
                        <td colspan="1" rowspan="1">12</td>
                        <td colspan="1" rowspan="1">18.2</td>
                        <td colspan="1" rowspan="1">19.0</td>
                        <td colspan="1" rowspan="1">4.2</td>
                        <td colspan="1" rowspan="1">39</td>
                        <td colspan="1" rowspan="1">23.8</td>
                        <td colspan="1" rowspan="1">61.9</td>
                        <td colspan="1" rowspan="1">13.5</td>
                        <td colspan="1" rowspan="1">12</td>
                        <td colspan="1" rowspan="1">20.3</td>
                        <td colspan="1" rowspan="1">19.0</td>
                        <td colspan="1" rowspan="1">4.2</td>
                        <td colspan="1" rowspan="1">63</td>
                        <td colspan="1" rowspan="1">21.8</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &gt;250 (n = 65)</td>
                        <td colspan="1" rowspan="1">15</td>
                        <td colspan="1" rowspan="1">22.7</td>
                        <td colspan="1" rowspan="1">23.1</td>
                        <td colspan="1" rowspan="1">5.2</td>
                        <td colspan="1" rowspan="1">37</td>
                        <td colspan="1" rowspan="1">22.6</td>
                        <td colspan="1" rowspan="1">56.9</td>
                        <td colspan="1" rowspan="1">12.8</td>
                        <td colspan="1" rowspan="1">13</td>
                        <td colspan="1" rowspan="1">22.0</td>
                        <td colspan="1" rowspan="1">20.0</td>
                        <td colspan="1" rowspan="1">4.5</td>
                        <td colspan="1" rowspan="1">65</td>
                        <td colspan="1" rowspan="1">22.5</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> No answer (n = 3)</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">1.2</td>
                        <td colspan="1" rowspan="1">66.7</td>
                        <td colspan="1" rowspan="1">0.7</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">1.7</td>
                        <td colspan="1" rowspan="1">33.3</td>
                        <td colspan="1" rowspan="1">0.3</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">1.0</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Total</td>
                        <td colspan="1" rowspan="1">66</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">22.8</td>
                        <td colspan="1" rowspan="1">164</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">56.8</td>
                        <td colspan="1" rowspan="1">59</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">289</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">.631</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">No. of submissions</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &lt;50 (n = 81)</td>
                        <td colspan="1" rowspan="1">20</td>
                        <td colspan="1" rowspan="1">30.3</td>
                        <td colspan="1" rowspan="1">24.7</td>
                        <td colspan="1" rowspan="1">6.9</td>
                        <td colspan="1" rowspan="1">45</td>
                        <td colspan="1" rowspan="1">27.4</td>
                        <td colspan="1" rowspan="1">55.6</td>
                        <td colspan="1" rowspan="1">15.6</td>
                        <td colspan="1" rowspan="1">16</td>
                        <td colspan="1" rowspan="1">27.1</td>
                        <td colspan="1" rowspan="1">19.8</td>
                        <td colspan="1" rowspan="1">5.5</td>
                        <td colspan="1" rowspan="1">81</td>
                        <td colspan="1" rowspan="1">28.0</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &lt;5000 (n = 159)</td>
                        <td colspan="1" rowspan="1">33</td>
                        <td colspan="1" rowspan="1">50.0</td>
                        <td colspan="1" rowspan="1">20.8</td>
                        <td colspan="1" rowspan="1">11.4</td>
                        <td colspan="1" rowspan="1">91</td>
                        <td colspan="1" rowspan="1">55.5</td>
                        <td colspan="1" rowspan="1">57.2</td>
                        <td colspan="1" rowspan="1">31.5</td>
                        <td colspan="1" rowspan="1">35</td>
                        <td colspan="1" rowspan="1">59.3</td>
                        <td colspan="1" rowspan="1">22.0</td>
                        <td colspan="1" rowspan="1">12.1</td>
                        <td colspan="1" rowspan="1">159</td>
                        <td colspan="1" rowspan="1">55.0</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &gt;5000 (n = 48)</td>
                        <td colspan="1" rowspan="1">13</td>
                        <td colspan="1" rowspan="1">19.7</td>
                        <td colspan="1" rowspan="1">27.1</td>
                        <td colspan="1" rowspan="1">4.5</td>
                        <td colspan="1" rowspan="1">27</td>
                        <td colspan="1" rowspan="1">16.5</td>
                        <td colspan="1" rowspan="1">56.3</td>
                        <td colspan="1" rowspan="1">9.3</td>
                        <td colspan="1" rowspan="1">8</td>
                        <td colspan="1" rowspan="1">13.6</td>
                        <td colspan="1" rowspan="1">16.7</td>
                        <td colspan="1" rowspan="1">2.8</td>
                        <td colspan="1" rowspan="1">48</td>
                        <td colspan="1" rowspan="1">16.6</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> No answer (n = 1)</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">0.6</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">0.3</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0.0</td>
                        <td colspan="1" rowspan="1">0.0</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">0.3</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Total</td>
                        <td colspan="1" rowspan="1">66</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">22.8</td>
                        <td colspan="1" rowspan="1">164</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">56.75</td>
                        <td colspan="1" rowspan="1">59</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">289</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">.877</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">No. of regulatory affairs employees</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &lt;50 (n = 157)</td>
                        <td colspan="1" rowspan="1">36</td>
                        <td colspan="1" rowspan="1">54.5</td>
                        <td colspan="1" rowspan="1">22.9</td>
                        <td colspan="1" rowspan="1">12.5</td>
                        <td colspan="1" rowspan="1">89</td>
                        <td colspan="1" rowspan="1">54.3</td>
                        <td colspan="1" rowspan="1">56.7</td>
                        <td colspan="1" rowspan="1">30.8</td>
                        <td colspan="1" rowspan="1">32</td>
                        <td colspan="1" rowspan="1">54.2</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">11.1</td>
                        <td colspan="1" rowspan="1">157</td>
                        <td colspan="1" rowspan="1">54.3</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &lt;100 (n = 36)</td>
                        <td colspan="1" rowspan="1">6</td>
                        <td colspan="1" rowspan="1">9.1</td>
                        <td colspan="1" rowspan="1">16.7</td>
                        <td colspan="1" rowspan="1">2.1</td>
                        <td colspan="1" rowspan="1">22</td>
                        <td colspan="1" rowspan="1">13.4</td>
                        <td colspan="1" rowspan="1">61.1</td>
                        <td colspan="1" rowspan="1">7.6</td>
                        <td colspan="1" rowspan="1">8</td>
                        <td colspan="1" rowspan="1">13.6</td>
                        <td colspan="1" rowspan="1">22.2</td>
                        <td colspan="1" rowspan="1">2.8</td>
                        <td colspan="1" rowspan="1">36</td>
                        <td colspan="1" rowspan="1">12.5</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &gt;100 (n = 93)</td>
                        <td colspan="1" rowspan="1">24</td>
                        <td colspan="1" rowspan="1">36.4</td>
                        <td colspan="1" rowspan="1">25.8</td>
                        <td colspan="1" rowspan="1">8.3</td>
                        <td colspan="1" rowspan="1">52</td>
                        <td colspan="1" rowspan="1">31.7</td>
                        <td colspan="1" rowspan="1">55.9</td>
                        <td colspan="1" rowspan="1">18.0</td>
                        <td colspan="1" rowspan="1">17</td>
                        <td colspan="1" rowspan="1">28.8</td>
                        <td colspan="1" rowspan="1">18.3</td>
                        <td colspan="1" rowspan="1">5.9</td>
                        <td colspan="1" rowspan="1">93</td>
                        <td colspan="1" rowspan="1">32.2</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> No answer (n = 3)</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">0.6</td>
                        <td colspan="1" rowspan="1">33.3</td>
                        <td colspan="1" rowspan="1">0.3</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">3.4</td>
                        <td colspan="1" rowspan="1">66.7</td>
                        <td colspan="1" rowspan="1">0.7</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">1.0</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Total</td>
                        <td colspan="1" rowspan="1">66</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">22.8</td>
                        <td colspan="1" rowspan="1">164</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">56.75</td>
                        <td colspan="1" rowspan="1">59</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">289</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">.769</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">No. of regulatory affairs external</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &lt;50 (n = 233)</td>
                        <td colspan="1" rowspan="1">60</td>
                        <td colspan="1" rowspan="1">90.9</td>
                        <td colspan="1" rowspan="1">25.8</td>
                        <td colspan="1" rowspan="1">20.8</td>
                        <td colspan="1" rowspan="1">131</td>
                        <td colspan="1" rowspan="1">79.9</td>
                        <td colspan="1" rowspan="1">56.2</td>
                        <td colspan="1" rowspan="1">45.3</td>
                        <td colspan="1" rowspan="1">42</td>
                        <td colspan="1" rowspan="1">71.2</td>
                        <td colspan="1" rowspan="1">18.0</td>
                        <td colspan="1" rowspan="1">14.5</td>
                        <td colspan="1" rowspan="1">233</td>
                        <td colspan="1" rowspan="1">80.6</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &lt;100 (n = 26)</td>
                        <td colspan="1" rowspan="1">4</td>
                        <td colspan="1" rowspan="1">6.1</td>
                        <td colspan="1" rowspan="1">15.4</td>
                        <td colspan="1" rowspan="1">1.4</td>
                        <td colspan="1" rowspan="1">17</td>
                        <td colspan="1" rowspan="1">10.4</td>
                        <td colspan="1" rowspan="1">65.4</td>
                        <td colspan="1" rowspan="1">5.9</td>
                        <td colspan="1" rowspan="1">5</td>
                        <td colspan="1" rowspan="1">8.5</td>
                        <td colspan="1" rowspan="1">19.2</td>
                        <td colspan="1" rowspan="1">1.7</td>
                        <td colspan="1" rowspan="1">26</td>
                        <td colspan="1" rowspan="1">9.0</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &gt;100 (n = 24)</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">3.0</td>
                        <td colspan="1" rowspan="1">8.3</td>
                        <td colspan="1" rowspan="1">0.7</td>
                        <td colspan="1" rowspan="1">12</td>
                        <td colspan="1" rowspan="1">7.3</td>
                        <td colspan="1" rowspan="1">50.0</td>
                        <td colspan="1" rowspan="1">4.2</td>
                        <td colspan="1" rowspan="1">10</td>
                        <td colspan="1" rowspan="1">16.9</td>
                        <td colspan="1" rowspan="1">41.7</td>
                        <td colspan="1" rowspan="1">3.5</td>
                        <td colspan="1" rowspan="1">24</td>
                        <td colspan="1" rowspan="1">8.3</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> No answer (n = 6)</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">4</td>
                        <td colspan="1" rowspan="1">2.4</td>
                        <td colspan="1" rowspan="1">66.7</td>
                        <td colspan="1" rowspan="1">1.4</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">3.4</td>
                        <td colspan="1" rowspan="1">33.3</td>
                        <td colspan="1" rowspan="1">0.7</td>
                        <td colspan="1" rowspan="1">6</td>
                        <td colspan="1" rowspan="1">2.1</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Total</td>
                        <td colspan="1" rowspan="1">66</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">22.8</td>
                        <td colspan="1" rowspan="1">164</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">56.75</td>
                        <td colspan="1" rowspan="1">59</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">289</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">.109</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">No. of information technology (IT) employees</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &lt;10 (n = 116)</td>
                        <td colspan="1" rowspan="1">31</td>
                        <td colspan="1" rowspan="1">47.0</td>
                        <td colspan="1" rowspan="1">26.7</td>
                        <td colspan="1" rowspan="1">10.7</td>
                        <td colspan="1" rowspan="1">63</td>
                        <td colspan="1" rowspan="1">38.4</td>
                        <td colspan="1" rowspan="1">54.3</td>
                        <td colspan="1" rowspan="1">21.8</td>
                        <td colspan="1" rowspan="1">22</td>
                        <td colspan="1" rowspan="1">37.3</td>
                        <td colspan="1" rowspan="1">19.0</td>
                        <td colspan="1" rowspan="1">7.6</td>
                        <td colspan="1" rowspan="1">116</td>
                        <td colspan="1" rowspan="1">40.1</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &lt;50 (n = 59)</td>
                        <td colspan="1" rowspan="1">13</td>
                        <td colspan="1" rowspan="1">19.7</td>
                        <td colspan="1" rowspan="1">22.0</td>
                        <td colspan="1" rowspan="1">4.5</td>
                        <td colspan="1" rowspan="1">31</td>
                        <td colspan="1" rowspan="1">18.9</td>
                        <td colspan="1" rowspan="1">52.5</td>
                        <td colspan="1" rowspan="1">10.7</td>
                        <td colspan="1" rowspan="1">15</td>
                        <td colspan="1" rowspan="1">25.4</td>
                        <td colspan="1" rowspan="1">25.4</td>
                        <td colspan="1" rowspan="1">5.2</td>
                        <td colspan="1" rowspan="1">59</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &gt;50 (n = 106)</td>
                        <td colspan="1" rowspan="1">21</td>
                        <td colspan="1" rowspan="1">31.8</td>
                        <td colspan="1" rowspan="1">19.8</td>
                        <td colspan="1" rowspan="1">7.3</td>
                        <td colspan="1" rowspan="1">67</td>
                        <td colspan="1" rowspan="1">40.9</td>
                        <td colspan="1" rowspan="1">63.2</td>
                        <td colspan="1" rowspan="1">23.2</td>
                        <td colspan="1" rowspan="1">18</td>
                        <td colspan="1" rowspan="1">30.5</td>
                        <td colspan="1" rowspan="1">17.0</td>
                        <td colspan="1" rowspan="1">6.2</td>
                        <td colspan="1" rowspan="1">106</td>
                        <td colspan="1" rowspan="1">36.7</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> No answer (n = 8)</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">1.5</td>
                        <td colspan="1" rowspan="1">13.0</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">1.8</td>
                        <td colspan="1" rowspan="1">37.5</td>
                        <td colspan="1" rowspan="1">1.0</td>
                        <td colspan="1" rowspan="1">4</td>
                        <td colspan="1" rowspan="1">6.8</td>
                        <td colspan="1" rowspan="1">50.0</td>
                        <td colspan="1" rowspan="1">1.4</td>
                        <td colspan="1" rowspan="1">8</td>
                        <td colspan="1" rowspan="1">2.8</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Total</td>
                        <td colspan="1" rowspan="1">66</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">22.8</td>
                        <td colspan="1" rowspan="1">164</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">56.75</td>
                        <td colspan="1" rowspan="1">59</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">289</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">.848</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">No. of IT external</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &lt;10 (n = 148)</td>
                        <td colspan="1" rowspan="1">35</td>
                        <td colspan="1" rowspan="1">53.0</td>
                        <td colspan="1" rowspan="1">23.6</td>
                        <td colspan="1" rowspan="1">12.1</td>
                        <td colspan="1" rowspan="1">76</td>
                        <td colspan="1" rowspan="1">46.3</td>
                        <td colspan="1" rowspan="1">51.4</td>
                        <td colspan="1" rowspan="1">26.3</td>
                        <td colspan="1" rowspan="1">37</td>
                        <td colspan="1" rowspan="1">62.7</td>
                        <td colspan="1" rowspan="1">25.0</td>
                        <td colspan="1" rowspan="1">12.8</td>
                        <td colspan="1" rowspan="1">148</td>
                        <td colspan="1" rowspan="1">51.2</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &lt;50 (n = 52)</td>
                        <td colspan="1" rowspan="1">10</td>
                        <td colspan="1" rowspan="1">15.2</td>
                        <td colspan="1" rowspan="1">19.2</td>
                        <td colspan="1" rowspan="1">3.5</td>
                        <td colspan="1" rowspan="1">32</td>
                        <td colspan="1" rowspan="1">19.5</td>
                        <td colspan="1" rowspan="1">61.5</td>
                        <td colspan="1" rowspan="1">11.1</td>
                        <td colspan="1" rowspan="1">10</td>
                        <td colspan="1" rowspan="1">16.9</td>
                        <td colspan="1" rowspan="1">19.2</td>
                        <td colspan="1" rowspan="1">3.5</td>
                        <td colspan="1" rowspan="1">52</td>
                        <td colspan="1" rowspan="1">18.0</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> &gt;50 (n = 79)</td>
                        <td colspan="1" rowspan="1">18</td>
                        <td colspan="1" rowspan="1">27.3</td>
                        <td colspan="1" rowspan="1">22.8</td>
                        <td colspan="1" rowspan="1">6.2</td>
                        <td colspan="1" rowspan="1">51</td>
                        <td colspan="1" rowspan="1">31.1</td>
                        <td colspan="1" rowspan="1">64.6</td>
                        <td colspan="1" rowspan="1">17.6</td>
                        <td colspan="1" rowspan="1">10</td>
                        <td colspan="1" rowspan="1">16.9</td>
                        <td colspan="1" rowspan="1">12.7</td>
                        <td colspan="1" rowspan="1">3.5</td>
                        <td colspan="1" rowspan="1">79</td>
                        <td colspan="1" rowspan="1">27.3</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> No answer (n = 10)</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">4.5</td>
                        <td colspan="1" rowspan="1">30.0</td>
                        <td colspan="1" rowspan="1">1.0</td>
                        <td colspan="1" rowspan="1">5</td>
                        <td colspan="1" rowspan="1">3.0</td>
                        <td colspan="1" rowspan="1">50.0</td>
                        <td colspan="1" rowspan="1">1.7</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">3.4</td>
                        <td colspan="1" rowspan="1">20.0</td>
                        <td colspan="1" rowspan="1">0.7</td>
                        <td colspan="1" rowspan="1">10</td>
                        <td colspan="1" rowspan="1">3.5</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Total</td>
                        <td colspan="1" rowspan="1">66</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">22.8</td>
                        <td colspan="1" rowspan="1">164</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">56.75</td>
                        <td colspan="1" rowspan="1">59</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">20.4</td>
                        <td colspan="1" rowspan="1">289</td>
                        <td colspan="1" rowspan="1">100.0</td>
                        <td colspan="1" rowspan="1">.302</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <fn id="table-fn2-0092861511427871">
                     <p>
                        <sup>a</sup>Multiple answers are possible.</p>
                  </fn>
               </table-wrap-foot>
            </table-wrap>
            <p>Most of the descriptive variables had no statistical significance. Only 1 statistically significant finding was detected (ie, the variable “location”). In addition, the variable “[number] # of regulatory affairs external” became apparent as a statistical trend.</p>
         </sec>
         <sec id="section5-0092861511427871">
            <title>Tool Costs and Paper Savings</title>
            <p>The first part of the dependent variables were costs for implementation and training, potential costs for migration efforts, and costs for additional IT spending. <xref ref-type="fig" rid="fig3-0092861511427871">Figures 3</xref>, <xref ref-type="fig" rid="fig4-0092861511427871">4</xref>, and <xref ref-type="fig" rid="fig5-0092861511427871">5</xref> show the breakdown between 3 (“additional IT costs,” question 19) and 6 (“implementation costs,” question 13; “migration costs,” question 14) different cost possibilities and percentages of answers for the United States, Europe, and RoW group differentiation and percentages of a subsequent total.</p>
            <fig id="fig3-0092861511427871" position="float">
               <label>Figure 3.</label>
               <caption>
                  <p>Electronic Common Technical Document (eCTD) implementation costs. RoW, rest of world.</p>
               </caption>
               <graphic alt-version="no" alternate-form-of="fig3-0092861511427871" position="float" xlink:href="10.1177_0092861511427871-fig3.tif" xlink:type="simple"/>
            </fig>
            <fig id="fig4-0092861511427871" position="float">
               <label>Figure 4.</label>
               <caption>
                  <p>Potential electronic Common Technical Document (eCTD) tool migration costs. RoW, rest of world.</p>
               </caption>
               <graphic alt-version="no" alternate-form-of="fig4-0092861511427871" position="float" xlink:href="10.1177_0092861511427871-fig4.tif" xlink:type="simple"/>
            </fig>
            <fig id="fig5-0092861511427871" position="float">
               <label>Figure 5.</label>
               <caption>
                  <p>Additional information technology (IT) costs for electronic Common Technical Document (eCTD) implementations. p.a., per annum; RoW, rest of world.</p>
               </caption>
               <graphic alt-version="no" alternate-form-of="fig5-0092861511427871" position="float" xlink:href="10.1177_0092861511427871-fig5.tif" xlink:type="simple"/>
            </fig>
            <p>In total, 10% did not answer the implementation costs question or have an eCTD tool in-house. Seventeen percent paid less than US$50,000, and another 17% paid more than US$1 million. Fifty-eight percent paid more than US$50,000 but less than US$1 million for their eCTD tool and directly related hardware and training costs. A total of 20% had no migration costs or no tool or did not answer this question. Forty-three percent had less than US$50,000 and 38% more than US$50,000 in migration costs (7% more than US$1 million). Almost two-thirds of the group had less than 15% additional IT costs per year through the eCTD implementation, and 22% had up to 25%. Seven percent of the total number has paid more than 25% per annum for product maintenance, additional IT archival costs, and so on for their initial eCTD tool investment.</p>
            <p>An average of more than 90% (97%, 96%, and 91%) of the “eCTD experience—existing” group participants were able to assess paper-related cost savings (savings in paper printing, handling, and archiving costs, question 20), including 154 cases (printing), 140 cases (handling), and 142 cases (archiving), which reflects a group average of 50% that were able to save 50% of their existing paper-based submission process-related paper costs and more. A maximum of 10 cases (average, 2%) did not answer this question, and only a maximum of 17 cases (average, 3%) had no paper savings (<xref ref-type="table" rid="table3-0092861511427871">Table 3</xref>).</p>
            <table-wrap id="table3-0092861511427871" position="float">
               <label>Table 3.</label>
               <caption>
                  <p>Paper Printing, Handling, and Archiving Cost Savings</p>
               </caption>
               <graphic alt-version="no" alternate-form-of="table3-0092861511427871" position="float" xlink:href="10.1177_0092861511427871-table3.tif" xlink:type="simple"/>
               <table>
                  <thead>
                     <tr>
                        <th colspan="1" rowspan="1">
</th>
                        <th colspan="2" rowspan="1">Value: –9 (No Answer)</th>
                        <th colspan="2" rowspan="1">Value: 1 (Improvement in T2A = 0%)</th>
                        <th colspan="2" rowspan="1">Value: 2 (Improvement in T2A &lt;10%)</th>
                        <th colspan="2" rowspan="1">Value: 3 (Improvement in T2A &lt;20%)</th>
                        <th colspan="2" rowspan="1">Value: 4 (Improvement in T2A &lt;30%)</th>
                        <th colspan="2" rowspan="1">Value: 5 (Improvement in T2A &lt;40%)</th>
                        <th colspan="2" rowspan="1">Value: 6 (Improvement in T2A ∼50%)</th>
                        <th colspan="2" rowspan="1">Value: 7 (Improvement in T2A &lt;75%)</th>
                        <th colspan="2" rowspan="1">Value: 8 (Improvement in T2A &gt;75%)</th>
                        <th colspan="4" rowspan="1">Total</th>
                     </tr>
                     <tr>
                        <th colspan="1" rowspan="1">Variable</th>
                        <th colspan="1" rowspan="1">No Answer</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">No Improvement</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;10%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;20%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;30%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;40%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">∼50%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;75%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&gt;75%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">Total (%)</th>
                        <th colspan="1" rowspan="1">∼50%+ (%)</th>
                        <th colspan="1" rowspan="1">&lt;10% vs &lt;40% (%)</th>
                        <th colspan="1" rowspan="1">With Improvement, %</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td colspan="1" rowspan="1">Cost savings</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> % Savings paper printing costs</td>
                        <td colspan="1" rowspan="1">4</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">6</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">33</td>
                        <td colspan="1" rowspan="1">11</td>
                        <td colspan="1" rowspan="1">38</td>
                        <td colspan="1" rowspan="1">13</td>
                        <td colspan="1" rowspan="1">34</td>
                        <td colspan="1" rowspan="1">12</td>
                        <td colspan="1" rowspan="1">20</td>
                        <td colspan="1" rowspan="1">7</td>
                        <td colspan="1" rowspan="1">47</td>
                        <td colspan="1" rowspan="1">16</td>
                        <td colspan="1" rowspan="1">43</td>
                        <td colspan="1" rowspan="1">15</td>
                        <td colspan="1" rowspan="1">64</td>
                        <td colspan="1" rowspan="1">22</td>
                        <td colspan="1" rowspan="1">289 (100)</td>
                        <td colspan="1" rowspan="1">154 (53)</td>
                        <td colspan="1" rowspan="1">125 (43)</td>
                        <td colspan="1" rowspan="1">97</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> % Savings paper handling costs</td>
                        <td colspan="1" rowspan="1">7</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">6</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">39</td>
                        <td colspan="1" rowspan="1">13</td>
                        <td colspan="1" rowspan="1">28</td>
                        <td colspan="1" rowspan="1">10</td>
                        <td colspan="1" rowspan="1">44</td>
                        <td colspan="1" rowspan="1">15</td>
                        <td colspan="1" rowspan="1">25</td>
                        <td colspan="1" rowspan="1">9</td>
                        <td colspan="1" rowspan="1">41</td>
                        <td colspan="1" rowspan="1">14</td>
                        <td colspan="1" rowspan="1">42</td>
                        <td colspan="1" rowspan="1">15</td>
                        <td colspan="1" rowspan="1">57</td>
                        <td colspan="1" rowspan="1">20</td>
                        <td colspan="1" rowspan="1">289 (100)</td>
                        <td colspan="1" rowspan="1">140 (48)</td>
                        <td colspan="1" rowspan="1">136 (47)</td>
                        <td colspan="1" rowspan="1">96</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> % Savings paper archiving costs</td>
                        <td colspan="1" rowspan="1">10</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">17</td>
                        <td colspan="1" rowspan="1">6</td>
                        <td colspan="1" rowspan="1">36</td>
                        <td colspan="1" rowspan="1">12</td>
                        <td colspan="1" rowspan="1">33</td>
                        <td colspan="1" rowspan="1">11</td>
                        <td colspan="1" rowspan="1">25</td>
                        <td colspan="1" rowspan="1">9</td>
                        <td colspan="1" rowspan="1">26</td>
                        <td colspan="1" rowspan="1">9</td>
                        <td colspan="1" rowspan="1">48</td>
                        <td colspan="1" rowspan="1">17</td>
                        <td colspan="1" rowspan="1">29</td>
                        <td colspan="1" rowspan="1">10</td>
                        <td colspan="1" rowspan="1">65</td>
                        <td colspan="1" rowspan="1">22</td>
                        <td colspan="1" rowspan="1">289 (100)</td>
                        <td colspan="1" rowspan="1">142 (49)</td>
                        <td colspan="1" rowspan="1">120 (42)</td>
                        <td colspan="1" rowspan="1">91</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="3" rowspan="1">Group average</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">50%</td>
                        <td colspan="1" rowspan="1">44%</td>
                        <td colspan="1" rowspan="1">94%</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <fn id="table-fn3-0092861511427871">
                     <p>T2A, time to approval.</p>
                  </fn>
               </table-wrap-foot>
            </table-wrap>
         </sec>
         <sec id="section6-0092861511427871">
            <title>Additional eCTD Advantages vs Disadvantages</title>
            <p>The variables “new processes (negative)” (question 17), “lack of standard consistency” (question 15), “use of hyperlinks, etc” (question 16), and “lack of qualified people” (question 18) were considered disadvantages. The variables “new processes (positive)” (question 22), “better life cycle support” (question 21), “searchable content and reuse” (question 23), “eCTD transfer” (question 24), and “better navigation and review” (question 25) were considered advantages. Again, the same 8-level scale (0%, &lt;10%, &lt;20%, &lt;30%, &lt;40%, ∼50%, &lt;75%, and &gt;75%) in time loss or improvement through the eCTD-based approach in comparison to the paper-based CTD approach was used. Each step stands for the answering values of 1, 2, 3, 4, 5, 6, 7, and 8. The answers are presented, including the associated percentages, in <xref ref-type="table" rid="table4-0092861511427871">Table 4</xref> and <xref ref-type="fig" rid="fig6-0092861511427871">Figure 6</xref>.</p>
            <fig id="fig6-0092861511427871" position="float">
               <label>Figure 6.</label>
               <caption>
                  <p>Congregated electronic Common Technical Document (eCTD) disadvantages and advantages: graphical overview. T2A, time to approval.</p>
               </caption>
               <graphic alt-version="no" alternate-form-of="fig6-0092861511427871" position="float" xlink:href="10.1177_0092861511427871-fig6.tif" xlink:type="simple"/>
            </fig>
            <table-wrap id="table4-0092861511427871" position="float">
               <label>Table 4.</label>
               <caption>
                  <p>Congregated eCTD Disadvantages/Advantages Overview</p>
               </caption>
               <graphic alt-version="no" alternate-form-of="table4-0092861511427871" position="float" xlink:href="10.1177_0092861511427871-table4.tif" xlink:type="simple"/>
               <table>
                  <thead>
                     <tr>
                        <th colspan="1" rowspan="1">
</th>
                        <th colspan="2" rowspan="1">Value: –9 (No Answer)</th>
                        <th colspan="2" rowspan="1">Value: 1 (Improvement or Loss in T2A = 0%)</th>
                        <th colspan="2" rowspan="1">Value: 2 (Improvement or Loss in T2A &lt;10%)</th>
                        <th colspan="2" rowspan="1">Value: 3 (Improvement or Loss in T2A &lt;20%)</th>
                        <th colspan="2" rowspan="1">Value: 4 (Improvement or Loss in T2A &lt;30%)</th>
                        <th colspan="2" rowspan="1">Value: 5 (Improvement or Loss in T2A &lt;40%)</th>
                        <th colspan="2" rowspan="1">Value: 6 (Improvement or Loss in T2A ∼50%)</th>
                        <th colspan="2" rowspan="1">Value: 7 (Improvement or Loss in T2A &lt;75%)</th>
                        <th colspan="2" rowspan="1">Value: 8 (Improvement or Loss in T2A &gt;75%)</th>
                        <th colspan="5" rowspan="1">Total</th>
                     </tr>
                     <tr>
                        <th colspan="1" rowspan="1">Variable</th>
                        <th colspan="1" rowspan="1">No Answer</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">No Loss in Time</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;10%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;20%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;30%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;40%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">∼50%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;75%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&gt;75%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">Total (%)</th>
                        <th colspan="1" rowspan="1">∼50%+ (%)</th>
                        <th colspan="1" rowspan="1">&lt;10% vs &lt;40% (%)</th>
                        <th colspan="1" rowspan="1">No Dis-advantage, %</th>
                        <th colspan="1" rowspan="1">
</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td colspan="1" rowspan="1">Disadvantages</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> New processes (negative)</td>
                        <td align="center" colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">33</td>
                        <td colspan="1" rowspan="1">11</td>
                        <td colspan="1" rowspan="1">90</td>
                        <td colspan="1" rowspan="1">31</td>
                        <td colspan="1" rowspan="1">67</td>
                        <td colspan="1" rowspan="1">23</td>
                        <td colspan="1" rowspan="1">52</td>
                        <td colspan="1" rowspan="1">18</td>
                        <td colspan="1" rowspan="1">21</td>
                        <td colspan="1" rowspan="1">7</td>
                        <td colspan="1" rowspan="1">16</td>
                        <td colspan="1" rowspan="1">6</td>
                        <td colspan="1" rowspan="1">6</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">289 (100)</td>
                        <td colspan="1" rowspan="1">25 (9)</td>
                        <td colspan="1" rowspan="1">230 (80)</td>
                        <td colspan="1" rowspan="1">11</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Lack of standard consistency</td>
                        <td align="center" colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">49</td>
                        <td colspan="1" rowspan="1">17</td>
                        <td colspan="1" rowspan="1">68</td>
                        <td colspan="1" rowspan="1">24</td>
                        <td colspan="1" rowspan="1">64</td>
                        <td colspan="1" rowspan="1">22</td>
                        <td colspan="1" rowspan="1">47</td>
                        <td colspan="1" rowspan="1">16</td>
                        <td colspan="1" rowspan="1">23</td>
                        <td colspan="1" rowspan="1">8</td>
                        <td colspan="1" rowspan="1">23</td>
                        <td colspan="1" rowspan="1">8</td>
                        <td colspan="1" rowspan="1">9</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">289 (100)</td>
                        <td colspan="1" rowspan="1">35 (12)</td>
                        <td colspan="1" rowspan="1">202 (70)</td>
                        <td colspan="1" rowspan="1">17</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Use of hyperlinks, etc</td>
                        <td align="center" colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">37</td>
                        <td colspan="1" rowspan="1">13</td>
                        <td colspan="1" rowspan="1">72</td>
                        <td colspan="1" rowspan="1">25</td>
                        <td colspan="1" rowspan="1">77</td>
                        <td colspan="1" rowspan="1">27</td>
                        <td colspan="1" rowspan="1">50</td>
                        <td colspan="1" rowspan="1">17</td>
                        <td colspan="1" rowspan="1">20</td>
                        <td colspan="1" rowspan="1">7</td>
                        <td colspan="1" rowspan="1">15</td>
                        <td colspan="1" rowspan="1">5</td>
                        <td colspan="1" rowspan="1">9</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">6</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">289 (100)</td>
                        <td colspan="1" rowspan="1">30 (10)</td>
                        <td colspan="1" rowspan="1">219 (76)</td>
                        <td colspan="1" rowspan="1">13</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Lack of qualified people</td>
                        <td align="center" colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">55</td>
                        <td colspan="1" rowspan="1">19</td>
                        <td colspan="1" rowspan="1">69</td>
                        <td colspan="1" rowspan="1">24</td>
                        <td colspan="1" rowspan="1">58</td>
                        <td colspan="1" rowspan="1">20</td>
                        <td colspan="1" rowspan="1">48</td>
                        <td colspan="1" rowspan="1">17</td>
                        <td colspan="1" rowspan="1">25</td>
                        <td colspan="1" rowspan="1">9</td>
                        <td colspan="1" rowspan="1">21</td>
                        <td colspan="1" rowspan="1">7</td>
                        <td colspan="1" rowspan="1">7</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">4</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">289 (100)</td>
                        <td colspan="1" rowspan="1">32 (11)</td>
                        <td colspan="1" rowspan="1">200 (69)</td>
                        <td colspan="1" rowspan="1">19</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Group average</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1"> </td>
                        <td colspan="1" rowspan="1">15%</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">11%</td>
                        <td colspan="1" rowspan="1">74%</td>
                        <td colspan="1" rowspan="1">15%</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                  </tbody>
               </table>
               <table>
                  <thead>
                     <tr>
                        <th colspan="1" rowspan="1">
</th>
                        <th colspan="1" rowspan="1">No Answer</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">No Improvement</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;10%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;20%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;30%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;40%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">∼50%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&lt;75%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">&gt;75%</th>
                        <th colspan="1" rowspan="1">% Total</th>
                        <th colspan="1" rowspan="1">Total (%)</th>
                        <th colspan="1" rowspan="1">∼50%+ (%)</th>
                        <th colspan="1" rowspan="1">&lt;10% vs &lt;40% (%)</th>
                        <th colspan="1" rowspan="1">With Improvement, %</th>
                        <th colspan="1" rowspan="1">
</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td colspan="1" rowspan="1">Advantages</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> New processes (positive)</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">21</td>
                        <td colspan="1" rowspan="1">7</td>
                        <td colspan="1" rowspan="1">39</td>
                        <td colspan="1" rowspan="1">13</td>
                        <td colspan="1" rowspan="1">56</td>
                        <td colspan="1" rowspan="1">19</td>
                        <td colspan="1" rowspan="1">38</td>
                        <td colspan="1" rowspan="1">13</td>
                        <td colspan="1" rowspan="1">26</td>
                        <td colspan="1" rowspan="1">9</td>
                        <td colspan="1" rowspan="1">53</td>
                        <td colspan="1" rowspan="1">18</td>
                        <td colspan="1" rowspan="1">22</td>
                        <td colspan="1" rowspan="1">8</td>
                        <td colspan="1" rowspan="1">33</td>
                        <td colspan="1" rowspan="1">11</td>
                        <td colspan="1" rowspan="1">289 (100)</td>
                        <td colspan="1" rowspan="1">108 (37)</td>
                        <td colspan="1" rowspan="1">159 (55)</td>
                        <td colspan="1" rowspan="1">92</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Better life cycle support</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">27</td>
                        <td colspan="1" rowspan="1">9</td>
                        <td colspan="1" rowspan="1">38</td>
                        <td colspan="1" rowspan="1">13</td>
                        <td colspan="1" rowspan="1">65</td>
                        <td colspan="1" rowspan="1">22</td>
                        <td colspan="1" rowspan="1">43</td>
                        <td colspan="1" rowspan="1">15</td>
                        <td colspan="1" rowspan="1">33</td>
                        <td colspan="1" rowspan="1">11</td>
                        <td colspan="1" rowspan="1">44</td>
                        <td colspan="1" rowspan="1">15</td>
                        <td colspan="1" rowspan="1">13</td>
                        <td colspan="1" rowspan="1">4</td>
                        <td colspan="1" rowspan="1">24</td>
                        <td colspan="1" rowspan="1">8</td>
                        <td colspan="1" rowspan="1">289 (100)</td>
                        <td colspan="1" rowspan="1">81 (28)</td>
                        <td colspan="1" rowspan="1">179 (62)</td>
                        <td colspan="1" rowspan="1">90</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Searchable content and reuse</td>
                        <td colspan="1" rowspan="1">5</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">16</td>
                        <td colspan="1" rowspan="1">6</td>
                        <td colspan="1" rowspan="1">47</td>
                        <td colspan="1" rowspan="1">16</td>
                        <td colspan="1" rowspan="1">45</td>
                        <td colspan="1" rowspan="1">16</td>
                        <td colspan="1" rowspan="1">40</td>
                        <td colspan="1" rowspan="1">14</td>
                        <td colspan="1" rowspan="1">23</td>
                        <td colspan="1" rowspan="1">8</td>
                        <td colspan="1" rowspan="1">39</td>
                        <td colspan="1" rowspan="1">13</td>
                        <td colspan="1" rowspan="1">32</td>
                        <td colspan="1" rowspan="1">11</td>
                        <td colspan="1" rowspan="1">42</td>
                        <td colspan="1" rowspan="1">15</td>
                        <td colspan="1" rowspan="1">289 (100)</td>
                        <td colspan="1" rowspan="1">113 (39)</td>
                        <td colspan="1" rowspan="1">155 (54)</td>
                        <td colspan="1" rowspan="1">93</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> eCTD transfer</td>
                        <td colspan="1" rowspan="1">4</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">19</td>
                        <td colspan="1" rowspan="1">7</td>
                        <td colspan="1" rowspan="1">50</td>
                        <td colspan="1" rowspan="1">17</td>
                        <td colspan="1" rowspan="1">34</td>
                        <td colspan="1" rowspan="1">12</td>
                        <td colspan="1" rowspan="1">30</td>
                        <td colspan="1" rowspan="1">10</td>
                        <td colspan="1" rowspan="1">30</td>
                        <td colspan="1" rowspan="1">10</td>
                        <td colspan="1" rowspan="1">48</td>
                        <td colspan="1" rowspan="1">17</td>
                        <td colspan="1" rowspan="1">33</td>
                        <td colspan="1" rowspan="1">11</td>
                        <td colspan="1" rowspan="1">41</td>
                        <td colspan="1" rowspan="1">14</td>
                        <td colspan="1" rowspan="1">289 (100)</td>
                        <td colspan="1" rowspan="1">122 (42)</td>
                        <td colspan="1" rowspan="1">144 (50)</td>
                        <td colspan="1" rowspan="1">92</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1"> Better navigation and review</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">1</td>
                        <td colspan="1" rowspan="1">10</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">35</td>
                        <td colspan="1" rowspan="1">12</td>
                        <td colspan="1" rowspan="1">36</td>
                        <td colspan="1" rowspan="1">12</td>
                        <td colspan="1" rowspan="1">31</td>
                        <td colspan="1" rowspan="1">11</td>
                        <td colspan="1" rowspan="1">24</td>
                        <td colspan="1" rowspan="1">8</td>
                        <td colspan="1" rowspan="1">53</td>
                        <td colspan="1" rowspan="1">18</td>
                        <td colspan="1" rowspan="1">36</td>
                        <td colspan="1" rowspan="1">12</td>
                        <td colspan="1" rowspan="1">61</td>
                        <td colspan="1" rowspan="1">21</td>
                        <td colspan="1" rowspan="1">289 (100)</td>
                        <td colspan="1" rowspan="1">150 (52)</td>
                        <td colspan="1" rowspan="1">126 (44)</td>
                        <td colspan="1" rowspan="1">96</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Group average</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1"> </td>
                        <td colspan="1" rowspan="1">6%</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">40%</td>
                        <td colspan="1" rowspan="1">53%</td>
                        <td colspan="1" rowspan="1">93%</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <fn id="table-fn4-0092861511427871">
                     <p>Abbreviations: eCTD, electronic Common Technical Document; T2A, time to approval.</p>
                  </fn>
               </table-wrap-foot>
            </table-wrap>
            <p>The group 1 (no improvement in time to approval), group 2 (improvement in time to approval &lt;40%), and group 3 (improvement in time to approval ≥50%) median averages of disadvantages were 3.26 for group 1, 3.04 for group 2, and 4.03 for group 3. For the advantages, median averages were 3.59 for group 1, 4.46 for group 2, and 6.10 for group 3. The associated subgroup deviation analysis (groups 1-3 and Europe, RoW, and United States) was created via subtraction of the related medians (advantages minus disadvantages), shown graphically in <xref ref-type="fig" rid="fig7-0092861511427871">Figure 7</xref>, and includes 2 trend lines.</p>
            <fig id="fig7-0092861511427871" position="float">
               <label>Figure 7.</label>
               <caption>
                  <p>Disadvantages and advantages: median subgroup deviation analysis. RoW, rest of world.</p>
               </caption>
               <graphic alt-version="no" alternate-form-of="fig7-0092861511427871" position="float" xlink:href="10.1177_0092861511427871-fig7.tif" xlink:type="simple"/>
            </fig>
            <p>Group 1 therefore indicated spreads between advantages and disadvantages, defined as median points, of 0.20 for Europe, –0.01 for RoW, and 1.03 for the United States. The deltas in group 2, with 1.23 for Europe, 1.23 for RoW, and 1.84 for the United States, were already extended. Group 3 contained the biggest gaps between the eCTD advantages and disadvantages: 1.79 for Europe, 1.49 for RoW, and a massive 3.22 for the United States.</p>
         </sec>
      </sec>
      <sec id="section7-0092861511427871">
         <title>Discussion</title>
         <p>
            <italic>Lean management</italic>, a successful method for years in industries other than the pharmaceutical industry, demands structured processes to increase efficiency without the loss of quality. Porsche Consulting performed a reference analysis between the automobile industry and the pharmaceutical industry in 2010 to help the pharmaceutical industry in its product development processes through lean management. The key findings were as follows: the need for cross-departmental process synchronization, more efficient procedures, and a more transparent overall process, as well as the need to determine standard procedures. They defined a full operating plan with different subprocesses such as market development, regulatory affairs, and production.</p>
         <p>The biggest potential they found was the reduction of pass-through time—or, as we specified it, time to approval (T2A). Medicinal products could be on the market considerably faster through optimization by avoiding waste in processes.<sup>
               <xref ref-type="bibr" rid="bibr35-0092861511427871">35</xref>
            </sup>
         </p>
         <p>Implementing eCTD can play an effective role toward successful lean management in the pharmaceutical industry and also to directly improve time to approval/market.</p>
         <sec id="section8-0092861511427871">
            <title>Baseline Characteristics</title>
            <p>Compared with the contact database fragmentation for the survey invitation, including 40% (8807 of 22,056) for Europe, 13% for RoW (2821 of 22,056), and 47% (10,428 of 22,056) for the United States, the analyzed group (n = 289) comprised 39% for Europe (112 of 289), 16% for RoW (46 of 289), and 45% for the United States (131 of 289) of those answering cases (ie, almost the same partition as the entire contact database).</p>
            <p>Fifty-five percent of the companies in the contact database were pharmaceutical and biotechnology companies (43% pharmaceutical + 12% biotechnology), 37% were generic companies, and 8% were service providers (total of 9106 represented companies). Answers from the results group included the following: 74% pharmaceutical and biotechnology companies, 12% generic companies, and 14% service providers (total of 289 group answers), which represented a bulge toward answers from pharmaceutical/biotechnology companies (+19 percentage points) and service providers (+6 percentage points) and a deficit in answers from generic companies (–25 percentage points).</p>
            <p>Because the size of the contact database companies only could be partitioned into companies with less than US$500 million revenue (2987 companies; 33%) and those with more than US$500 million revenue (6119 companies; 67%), we also needed to assemble companies with up to US$3 billion revenue and those with more than US$3 billion revenue for comparability reasons. Therefore, the results group included 42% of companies with up to US$500 million revenue (+9 percentage points) and 56% of companies with more than US$500 million revenue (–11 percentage points). Two percent of the results group did not respond to this classification question.</p>
         </sec>
         <sec id="section9-0092861511427871">
            <title>Tool Costs and Paper Savings</title>
            <p>With respect to eCTD implementation cost, the United States invested more than RoW and Europe for the tool (software) as well as for related hardware and training. The highest cost for migration was paid by RoW, followed by the United States. Europe had the lowest cost for migrating from an old e-submission tool to the new eCTD tool, we believe the reason for this that very few non-eCTD e-submission tools existed in Europe. RoW had to bear the highest cost for additional IT (16% paid more than 25% per year for follow-on cost related to the eCTD implementation project), followed by the United States and Europe. In total, the United States initially paid more but had to bear less follow-on maintenance and additional IT costs. The same, but vice versa, is true for RoW. Europe was the economic leader for the direct cost factor. It had the lowest implementation, migration, and additional IT costs.</p>
            <p>Paper cost savings were enormous. Even group 1 (without improvement in time to approval through eCTD) reached an average level of 5.01 across all 3 items (paper printing, handling, and archival costs), which means that up to 40% of all relevant paper costs were saved through eCTD. The event rate in group 2 was similar, with a 5.03 average, and group 3 was even able to reach a 5.94 average, thus saving 50% or more in applicable paper costs. This eCTD-related cost saving alone is able to offset the complete eCTD investment.<sup>
                  <xref ref-type="bibr" rid="bibr36-0092861511427871">36</xref>
               </sup>
            </p>
         </sec>
         <sec id="section10-0092861511427871">
            <title>Additional eCTD Advantages vs Disadvantages</title>
            <sec id="section11-0092861511427871">
               <title>General Advantages vs Disadvantages</title>
               <p>This study showed that 223 of 289 respondents (77.2%) with experience in submitting 1 or more eCTD sequences for review by a regulatory authority (called “eCTD experience existing” in this study) were able to reduce their time to approval with an eCTD-based approach compared to a paper-based approach, whereas only 22.8% did not report a reduction. A large segment, 20.4% of respondents, reported 50% or more reduction in time to approval.</p>
               <p>However, implementing eCTD has always included both advantages and disadvantages with regard to the previously existing paper-based CTD approach. In general, the 4 disadvantages together (“new processes (negative),” “lack of standard consistency,” “use of hyperlinks, etc,” and “lack of qualified people”) caused a time loss of up to 40% in an average of 74% of cases. Only an average of 11%, however, faced 50% or more time loss because of these eCTD disadvantages, and 15% had no time loss at all. The graphical overview shown in <xref ref-type="fig" rid="fig6-0092861511427871">Figure 6</xref> highlights the pattern of the mostly similar responses for eCTD disadvantages. The peaks were between &lt;10% and &lt;30% time loss, and fewer respondents reported higher time losses (eg, ≥50%).</p>
               <p>For the eCTD advantages section of the survey, in which the response choices were “new processes (positive),” “better life cycle support,” “searchable content and reuse,” “eCTD transfer,” and “better navigation and review,” the pattern of responses was more varied than the eCTD disadvantages section. However, an average of 93% was able to save process time through eCTD, and 40% saved even more than half of the time. Graphically, it became obvious that considerably more eCTD advantages responses were given for the 50% and more categories than eCTD disadvantages.</p>
            </sec>
            <sec id="section12-0092861511427871">
               <title>Particular Advantages vs Disadvantages</title>
               <p>By dividing the study results into the 3 groups defined in <xref ref-type="fig" rid="fig2-0092861511427871">Figure 2</xref> (group 1, no improvement in time to approval; group 2, improvement in time to approval &lt;40%; and group 3, improvement in time to approval ≥50%) and 3 subcategories (Europe, RoW, and United States), new aspects appeared.</p>
               <p>Group 1 had the lowest advantages values in comparison to group 2 or group 3 but not the lowest disadvantages values, resulting in a very small advantages/disadvantages spread. In group 2, not only the advantages values increased but also the disadvantages values overall decreased, which increased the spread meaningfully. Last, within group 3, all values were highest but also had the widest spreads. It also became evident that all advantages/disadvantages spreads in the United States were the widest due to the best advantages values in each group, and the RoW spreads were the tightest. Having said this, the advantages values of RoW were still higher than those for Europe in every group.</p>
               <p>This implies that, in total, the most successful eCTD facilitating companies had the best advantages with widest spreads to the disadvantages, although the disadvantages values were not necessarily the lowest (<xref ref-type="fig" rid="fig7-0092861511427871">Figure 7</xref>).</p>
               <p>As already mentioned in the Results section, with statistical significance (<italic>P</italic> &lt; .001), the location of the represented companies was an overall key value driver. The responses for the United States and RoW were more positive than for Europe. We can think of 3 possible reasons for the significant difference between the United States and Europe.</p>
               <p>First, the United States has only 1 regulatory authority, the US Food and Drug Administration (FDA),<sup>
                     <xref ref-type="bibr" rid="bibr37-0092861511427871">37</xref>
                  </sup> and Europe is a conglomerate of a minimum of 32 national competent authorities (NCAs) plus the EMA.<sup>
                     <xref ref-type="bibr" rid="bibr31-0092861511427871">31</xref>
                  </sup> Even an EMA representative sees that “the European environment is a complex one in which to introduce new systems and processes.”<sup>
                     <xref ref-type="bibr" rid="bibr38-0092861511427871">38</xref>
                  </sup>
               </p>
               <p>Second, the FDA was earlier in mandating eCTD for electronic submissions: since January 2008, the FDA has withdrawn “three electronic submission guidances in favor of eCTD.”<sup>
                     <xref ref-type="bibr" rid="bibr21-0092861511427871">21</xref>
                  </sup> In contrast, eCTD in Europe was made mandatory for electronic submissions for the centralized procedure only since January 2010.<sup>
                     <xref ref-type="bibr" rid="bibr23-0092861511427871">23</xref>
                  </sup> But by the end of 2009, only 84% of all NCAs in Europe were electronic submission ready, and more than 50% of the total number of applications in Europe per procedure were national procedure applications.<sup>
                     <xref ref-type="bibr" rid="bibr31-0092861511427871">31</xref>
                  </sup>
               </p>
               <p>Third is the existence of the electronic submission gateway (ESG) at the FDA since 2008. More than 75% of electronic submissions are currently sent through the ESG, and it is the FDA’s preferred method of receipt.<sup>
                     <xref ref-type="bibr" rid="bibr39-0092861511427871">39</xref>,<xref ref-type="bibr" rid="bibr40-0092861511427871">40</xref>
                  </sup> The European version of it is still in development and already delayed by more than 9 months.<sup>
                     <xref ref-type="bibr" rid="bibr41-0092861511427871">41</xref>
                  </sup>
               </p>
               <p>Also important is the trend found through statistical methods: the number of external regulatory affairs people used within the respondents’ companies was also a key value driver. Although 90.9% of group 1 members articulated less than 50 external resources and 8.3% more than 100 external resources, only 71.2% of group 3 members indicated less than 50 external resources but 16.9% more than 100 external resources within regulatory affairs.</p>
               <p>In our opinion, this has to do with the fact that external consultants with eCTD experience had already been involved in several different eCTD projects in different companies, with different tools, processes, and so on.<sup>
                     <xref ref-type="bibr" rid="bibr15-0092861511427871">15</xref>
                  </sup> They gained a lot of experience and created a huge knowledge base, which was usually not present within internal regulatory affairs at the sponsor company. These external consultants, clearly aware of the eCTD advantages, have tried to push an eCTD adoption for years.<sup>
                     <xref ref-type="bibr" rid="bibr42-0092861511427871">42</xref>
                     <xref ref-type="bibr" rid="bibr43-0092861511427871"/>
                     <xref ref-type="bibr" rid="bibr44-0092861511427871"/>
                     <xref ref-type="bibr" rid="bibr45-0092861511427871"/>
                     <xref ref-type="bibr" rid="bibr46-0092861511427871"/>–<xref ref-type="bibr" rid="bibr47-0092861511427871">47</xref>
                  </sup>
               </p>
               <p>Interestingly, no other descriptive variable had additional influence on the success of eCTD, including the kind of company, company size, chief information officer in charge, the number of products or submissions, number of internal regulatory affairs employees, or the number of internal or external IT persons.</p>
            </sec>
            <sec id="section13-0092861511427871">
               <title>Other Studies</title>
               <p>Other studies in the same area of interest (eCTD) conducted by “C5” in 2010,<sup>
                     <xref ref-type="bibr" rid="bibr48-0092861511427871">48</xref>
                  </sup> Steve Gens and colleagues in 2007 and 2009,<sup>
                     <xref ref-type="bibr" rid="bibr49-0092861511427871">49</xref>,<xref ref-type="bibr" rid="bibr50-0092861511427871">50</xref>
                  </sup> Liquent/Thomson/Reuters Research between 2005 and 2009,<sup>
                     <xref ref-type="bibr" rid="bibr51-0092861511427871">51</xref>
                     <xref ref-type="bibr" rid="bibr52-0092861511427871"/>
                     <xref ref-type="bibr" rid="bibr53-0092861511427871"/>
                     <xref ref-type="bibr" rid="bibr54-0092861511427871"/>–<xref ref-type="bibr" rid="bibr55-0092861511427871">55</xref>
                  </sup> Lorenz in 2008,<sup>
                     <xref ref-type="bibr" rid="bibr56-0092861511427871">56</xref>
                  </sup> Pharma iQ in 2010,<sup>
                     <xref ref-type="bibr" rid="bibr57-0092861511427871">57</xref>
                  </sup> and Unicus in 2007<sup>
                     <xref ref-type="bibr" rid="bibr58-0092861511427871">58</xref>
                  </sup> used different respondent classification (eg, location, kind of company), and therefore it was nearly impossible to directly compare these independent values. In addition, they generally did not ask for eCTD advantages but rather for the current status of existing eCTD implementation and potential future plans for migration. For eCTD disadvantages, they often used free text comments of respondents, which were not categorized and therefore not measurable. Generally, these studies were vendor driven, with a small number of respondents (most had &lt;150), and some were not completed (Lorenz and Unicus). In addition, some did not ask for quantitative eCTD advantages or disadvantages or eCTD tool costs and related paper cost savings.</p>
               <p>On the other hand, the Pharma iQ survey of 2010 had one very interesting observation in line with our study. It asked, “Do electronic submissions save pharmaceutical companies time?” and in total, 62.1% responded positively and 20.7% even declared a “much faster” submission process. Of the respondents, 17.2% declared that “it takes the same amount of time.” This corresponds closely to our results of 77.2% with improvement in time to approval, 20.4% with 50% or more time savings, and 22.8% with no improvement. The “much faster” answers (20.7% vs 20.4%) and the no-improvement answers (17.2% vs 22.8%) were almost identical to our results.<sup>
                     <xref ref-type="bibr" rid="bibr59-0092861511427871">59</xref>
                  </sup>
               </p>
            </sec>
         </sec>
         <sec id="section14-0092861511427871">
            <title>Study Limitations</title>
            <p>One limitation of this study is the existence of the group “eCTD experience—not existing” (n = 108). This group provided substantially different answers than the group “eCTD experience—existing.” On average, it rated eCTD disadvantages higher and eCTD advantages lower than the comparison group. In addition, it also undervalued the costs for implementation, training, and additional IT spending. Conversely, this group had not “submitted one or more eCTD sequences for review by a regulatory authority” or—as we defined it—had no eCTD experience. For this reason, we decided to consider only the answers of the “eCTD experience—existing” group for the previous results discussion.</p>
            <p>Another major limitation of small studies such as this one is the occurrence of false-positive results or the overestimation of the magnitude of an association. With 289 cases out of 22,056 contacts invited, we only achieved 1.3%. However, in comparison with the existing eCTD studies, our achievement of 289 highly qualified answers is in the top range.</p>
         </sec>
      </sec>
      <sec id="section15-0092861511427871">
         <title>Conclusion</title>
         <p>Every kind of appropriate company submitting or planning to submit dossiers to an ICH supporting authority can gain advantages through implementing the eCTD. At a minimum, such companies profit from considerable savings in paper printing, handling, and archival costs but ideally also benefit from a substantial savings with respect to time to approval for medicinal products.</p>
         <p>The results showed that the location of the companies positively influenced the values attached to eCTD to a statistically significant degree. Best values included the United States, followed by RoW; Europe had the worst values. In contrast, variables such as kind of company, company size, chief information officer in charge, the number of products or submissions, number of internal regulatory affairs employees, or the number of internal or external IT persons had no influence on the main goal of reducing time to approval (ie, time to market for pharmaceutical products). However, the number of external regulatory affairs people supporting the eCTD pattern change had an enormous impact on such reduction goal. Therefore, it is critical for companies aiming to benefit from the advantages of eCTD to contract an adequate number of experienced people first and then work on a dedicated knowledge transfer to the internal regulatory affairs employees as soon as possible. If this is not possible, the companies should investigate the possibility of long-term external contracts.</p>
         <p>By dividing the study results into the 3 groups—group 1 (no improvement in time to approval), group 2 (improvement in time to approval &lt;40%), and group 3 (improvement in time to approval ≥50%)—new insights appeared. The most successful eCTD facilitating companies had the best advantages with widest spreads to the disadvantages, although the disadvantages values were not necessarily the lowest.</p>
         <p>In conclusion, the authors concur with Katz’s statement<sup>
               <xref ref-type="bibr" rid="bibr59-0092861511427871">59</xref>
            </sup>: “eCTD is here to stay.” However, its successful implementation requires a strategic decision to be made. The sooner such a decision is made and the more the required changes will be supported, the greater the benefits can be.</p>
      </sec>
   </body>
   <back>
      <ack>
         <title>Acknowledgments</title>
         <p>The authors are grateful to Dr Hans-Georg Wagner, head of information and communications technology for the survey support of the European Medicines Agency (EMA), and to more than 50 associations, agencies, vendors and individuals to spread the survey invitation to more than 22,000 drug regulatory professionals worldwide.</p>
      </ack>
      <fn-group>
         <fn fn-type="conflict" id="fn1-0092861511427871">
            <p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
         </fn>
         <fn fn-type="financial-disclosure" id="fn2-0092861511427871">
            <p>The author(s) received no financial support for the research, authorship, and/or publication of this article. </p>
         </fn>
      </fn-group>
      <ref-list>
         <title>References</title>
         <ref id="bibr1-0092861511427871">
            <label>1</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Menges</surname>
                     <given-names>K</given-names>
                  </name>
               </person-group>. <article-title>Die Harmonisierung des Zulassungsdossiers: Perspektiven einheitlicher Vorgaben</article-title>. <source>Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz</source>. <year>2008</year>;<volume>51</volume>:<fpage>748</fpage>–<lpage>756</lpage>.</citation>
         </ref>
         <ref id="bibr2-0092861511427871">
            <label>2</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Menges</surname>
                     <given-names>K</given-names>
                  </name>
               </person-group>. <article-title>Elektronische Einreichung von Zulassungsdossiers bei den Behörden</article-title>. <source>Pharm Ind 72</source>. <year>2010</year>;<volume>7</volume>:<fpage>1148</fpage>–<lpage>1158</lpage>.</citation>
         </ref>
         <ref id="bibr3-0092861511427871">
            <label>3</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">International Conference on Harmonisation</collab>. <source>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use</source>. <ext-link ext-link-type="uri" xlink:href="http://www.ich.org" xlink:type="simple">http://www.ich.org</ext-link>. <comment>Accessed May 2011</comment>.</citation>
         </ref>
         <ref id="bibr4-0092861511427871">
            <label>4</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">eSubmission</collab>. <article-title>What is eSubmission?</article-title> 
               <month>April</month> 
               <day>14</day>, <year>2010</year>. <ext-link ext-link-type="uri" xlink:href="http://esubmission.ema.europa.eu/whatisesubmission.htm" xlink:type="simple">http://esubmission.ema.europa.eu/whatisesubmission.htm</ext-link>. <comment>Accessed May 2011</comment>.</citation>
         </ref>
         <ref id="bibr5-0092861511427871">
            <label>5</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">European Medicines Agency</collab>. <source>Practical Guidance for the Paper Submission of Regulatory Information in Support of a Marketing Authorisation Application When Using the Electronic Common Technical Document (“eCTD”) as the Source Submission</source>. <month>February</month> 
               <year>2006</year>. <ext-link ext-link-type="uri" xlink:href="http://ec.europa.eu/health/files/eudralex/vol-2/b/ectd_01-20006/ectdpaperv1.0.pdf" xlink:type="simple">http://ec.europa.eu/health/files/eudralex/vol-2/b/ectd_01-20006/ectdpaperv1.0.pdf</ext-link>
            </citation>
         </ref>
         <ref id="bibr6-0092861511427871">
            <label>6</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Kuhnert</surname>
                     <given-names>BR</given-names>
                  </name>
               </person-group>. <article-title>ICH at 20: an overview</article-title>. <source>Global Forum</source>. <year>2011</year>;<volume>3</volume>(<issue>2</issue>):<fpage>17</fpage>–<lpage>18</lpage>.</citation>
         </ref>
         <ref id="bibr7-0092861511427871">
            <label>7</label>
            <citation citation-type="web" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Goel</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Sundaranjan</surname>
                     <given-names>MK</given-names>
                  </name>
               </person-group>. <article-title>Managing electronic submission through eCTD with strategic partners</article-title>. <year>2006</year>. <ext-link ext-link-type="uri" xlink:href="http://www.eyeforpharma.com/briefing/ectdfinal.pdf" xlink:type="simple">http://www.eyeforpharma.com/briefing/ectdfinal.pdf</ext-link>
            </citation>
         </ref>
         <ref id="bibr8-0092861511427871">
            <label>8</label>
            <citation citation-type="web" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Benning</surname>
                     <given-names>L</given-names>
                  </name>
               </person-group>. <article-title>Electronic submission and the MRP/DCP: how to compile a dossier that will be accepted at the European agencies</article-title>. <year>2007</year>. <ext-link ext-link-type="uri" xlink:href="http://www.dgra.de/studiengang/pdf/master_benning_l.pdf" xlink:type="simple">http://www.dgra.de/studiengang/pdf/master_benning_l.pdf</ext-link>
            </citation>
         </ref>
         <ref id="bibr9-0092861511427871">
            <label>9</label>
            <citation citation-type="journal" xlink:type="simple">
               <article-title>Guidance for industry: providing regulatory submissions in electronic format—human pharmaceutical product applications and related submissions using the eCTD specifications</article-title>. <source>Biotechnol Law Rep</source>. <year>2006</year>;<volume>25</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>45</lpage>.</citation>
         </ref>
         <ref id="bibr10-0092861511427871">
            <label>10</label>
            <citation citation-type="book" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Kershaw</surname>
                     <given-names>P</given-names>
                  </name>
               </person-group>. <source>Submission of the Dossier: Update on Electronic Submission and PIM—1st EMA workshop for Micro, Small and Medium-Sized Enterprises (SMEs)</source>. <publisher-loc>London</publisher-loc>: <publisher-name>European Medicines Agency (EMA</publisher-name>); <year>2007</year>.</citation>
         </ref>
         <ref id="bibr11-0092861511427871">
            <label>11</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Lakkis</surname>
                     <given-names>MM</given-names>
                  </name>
               </person-group>. <article-title>Global and regional drug regulatory harmonization initiatives</article-title>. <source>Drug Inf J</source>. <year>2010</year>;<volume>44</volume>:<fpage>289</fpage>–<lpage>297</lpage>.</citation>
         </ref>
         <ref id="bibr12-0092861511427871">
            <label>12</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Molzon</surname>
                     <given-names>JA</given-names>
                  </name>
               </person-group>. <article-title>The value and benefits of International Conference on Harmonization (ICH) to regulators: the common technical document as a common regulatory language</article-title>. <source>Global Forum</source>. <year>2011</year>;<volume>3</volume>:<fpage>12</fpage>–<lpage>14</lpage>.</citation>
         </ref>
         <ref id="bibr13-0092861511427871">
            <label>13</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">International Conference on Harmonisation (ICH)</collab>. <source>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH Looks Ahead to the Next Decade: Further Expansion to Non-ICH Regions</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>ICH</publisher-name>; <year>2011</year>.</citation>
         </ref>
         <ref id="bibr14-0092861511427871">
            <label>14</label>
            <citation citation-type="web" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Al Mesned</surname>
                     <given-names>A</given-names>
                  </name>
               </person-group>. <article-title>Installation of ‘EURS is Yours’ at SaudiFDA for review of electronic dossiers in 2007</article-title>. <ext-link ext-link-type="uri" xlink:href="http://jobousephk.netne.net/aboutus.html" xlink:type="simple">http://jobousephk.netne.net/aboutus.html</ext-link>. <comment>Accessed May 2011</comment>.</citation>
         </ref>
         <ref id="bibr15-0092861511427871">
            <label>15</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Suchanek</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Ostermann</surname>
                     <given-names>H</given-names>
                  </name>
               </person-group>. <article-title>Evaluating the process of the pattern change from paper based to electronic submissions of medicinal products</article-title>. <source>Pharm Ind 71</source>. <year>2009</year>;<volume>9</volume>:<fpage>1526</fpage>–<lpage>1532</lpage>.</citation>
         </ref>
         <ref id="bibr16-0092861511427871">
            <label>16</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">World Health Organization</collab>. <source>How to Implement Computer-Assisted Drug Registration: A Practical Guide for Drug Regulatory Authorities</source>. <comment>Regulatory Support Series No. 002</comment>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>1998</year>. <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/medicinedocs/en/d/Jh2994e/" xlink:type="simple">http://apps.who.int/medicinedocs/en/d/Jh2994e/</ext-link>
            </citation>
         </ref>
         <ref id="bibr17-0092861511427871">
            <label>17</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Molzon</surname>
                     <given-names>J</given-names>
                  </name>
               </person-group>. <article-title>The common technical document: the changing face of the new drug application</article-title>. <source>Nat Rev</source>. <year>2003</year>;<volume>2</volume>:<fpage>71</fpage>–<lpage>74</lpage>.</citation>
         </ref>
         <ref id="bibr18-0092861511427871">
            <label>18</label>
            <citation citation-type="book" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Goater</surname>
                     <given-names>L</given-names>
                  </name>
               </person-group>. <source>Current Status of e-Submissions</source>. <publisher-loc>London</publisher-loc>: <publisher-name>Medicines and Healthcare products Regulatory Agency (MHRA</publisher-name>); <year>2009</year>.</citation>
         </ref>
         <ref id="bibr19-0092861511427871">
            <label>19</label>
            <citation citation-type="book" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Schnitzler</surname>
                     <given-names>J</given-names>
                  </name>
               </person-group>. <source>Das eCTD—Grundlagen, Vokabular</source>. <publisher-loc>Olten, Switzerland</publisher-loc>: <publisher-name>MEGRA ProAktiv Schweiz, Regulatory Training</publisher-name>; <year>2009</year>.</citation>
         </ref>
         <ref id="bibr20-0092861511427871">
            <label>20</label>
            <citation citation-type="confproc" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Järmann</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Zerobin Kleist</surname>
                     <given-names>C</given-names>
                  </name>
               </person-group>. <article-title>eCTD aus Perspektive der Behörde—Die Einführung von eSubmissions bei Swissmedic</article-title>. <conf-name>Presented at: MEGRA Seminar</conf-name>; <month>September</month> 
               <day>18</day>, <year>2009</year>; <conf-loc>Olten, Switzerland</conf-loc>.</citation>
         </ref>
         <ref id="bibr21-0092861511427871">
            <label>21</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Drug Information Association (DIA)</collab>. <article-title>Pharmaceutical online: FDA withdraws three electronic submission guidances in favor of eCTD</article-title>. <month>November</month> 
               <year>2007</year>. <ext-link ext-link-type="uri" xlink:href="http://www.pharmaceuticalonline.com/article.mvc/FDA-Withdraws-Three-Electronic-Submission-Gui-0001?VNETCOOKIE=NO" xlink:type="simple">http://www.pharmaceuticalonline.com/article.mvc/FDA-Withdraws-Three-Electronic-Submission-Gui-0001?VNETCOOKIE=NO</ext-link>. <comment>Accessed June 2011</comment>.</citation>
         </ref>
         <ref id="bibr22-0092861511427871">
            <label>22</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">European Medicines Agency (EMA)</collab>. <source>EMEA Implementation of Electronic-Only Submissions and eCTD Submissions in the Centralized Procedure: Statement of Intent</source>. <publisher-loc>London</publisher-loc>: <publisher-name>EMA</publisher-name>; <year>2008</year>. <comment>EMEA/563366/2007</comment>
            </citation>
         </ref>
         <ref id="bibr23-0092861511427871">
            <label>23</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">European Medicines Agency (EMA)</collab>. <source>EMEA Implementation of Electronic-Only Submissions and Mandatory eCTD Submissions in the Centralized Procedure: Statement of Intent</source>. <publisher-loc>London</publisher-loc>: <publisher-name>EMA</publisher-name>; <year>2008</year>. <comment>EMEA/572459/2008</comment>
            </citation>
         </ref>
         <ref id="bibr24-0092861511427871">
            <label>24</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">INFARMED announces eSubmission roadmap; eCTD mandatory starting 2012. July 20,</collab>. <year>2010</year>. <ext-link ext-link-type="uri" xlink:href="http://www.exalon.com/news/news-archiv-details/article/pt-infarmed-announces-esubmission-roadmap-ectd-mandatory-starting-2012.html" xlink:type="simple">http://www.exalon.com/news/news-archiv-details/article/pt-infarmed-announces-esubmission-roadmap-ectd-mandatory-starting-2012.html</ext-link>. <comment>Accessed May 2011</comment>.</citation>
         </ref>
         <ref id="bibr25-0092861511427871">
            <label>25</label>
            <citation citation-type="web" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Felgate</surname>
                     <given-names>T</given-names>
                  </name>
               </person-group>. <article-title>The evolution of the eCTD</article-title>. <month>March</month> 
               <year>2009</year>. <ext-link ext-link-type="uri" xlink:href="http://www.europeanregulatory.com/articles/FelgateTPharmafocusMarch2009.pdf." xlink:type="simple">http://www.europeanregulatory.com/articles/FelgateTPharmafocusMarch2009.pdf</ext-link>
            </citation>
         </ref>
         <ref id="bibr26-0092861511427871">
            <label>26</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">European Medicines Agency (EMA)</collab>. <article-title>European Medicines Agency closes PIM project</article-title>. <month>March</month> 
               <day>28</day>, <year>2011</year>. <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/03/news_detail_001233.jsp&amp;mid=WC0b01ac058004d5c1&amp;murl=menus/news_and_events/news_and_events.jsp&amp;jsenabled=true" xlink:type="simple">http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/03/news_detail_001233.jsp&amp;mid=WC0b01ac058004d5c1&amp;murl=menus/news_and_events/news_and_events.jsp&amp;jsenabled=true</ext-link>
            </citation>
         </ref>
         <ref id="bibr27-0092861511427871">
            <label>27</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Van Belkum</surname>
                     <given-names>S</given-names>
                  </name>
               </person-group>. <article-title>Electronic submissions: past, present and future</article-title>. <source>J Eur Med Writers Assoc</source>. <year>2006</year>;<volume>15</volume>(<issue>1</issue>):<fpage>85</fpage>–<lpage>88</lpage>.</citation>
         </ref>
         <ref id="bibr28-0092861511427871">
            <label>28</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">International Conference on Harmonisation (ICH)</collab>. <source>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use</source>. <comment>M8: Electronic Common Technical Document</comment>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>ICH</publisher-name>; <year>2010</year>.</citation>
         </ref>
         <ref id="bibr29-0092861511427871">
            <label>29</label>
            <citation citation-type="web" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>De Haan</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Nixon</surname>
                     <given-names>A</given-names>
                  </name>
               </person-group>. <article-title>Paperless submission: current situation within the EU</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.pda.org/Presentation/PDAEMA-2011-Conference/Track-3--4-Rob-de-Haan-Alastair-Nixon.aspx" xlink:type="simple">http://www.pda.org/Presentation/PDAEMA-2011-Conference/Track-3--4-Rob-de-Haan-Alastair-Nixon.aspx</ext-link>. <comment>Accessed June 2011</comment>.</citation>
         </ref>
         <ref id="bibr30-0092861511427871">
            <label>30</label>
            <citation citation-type="confproc" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gensinger</surname>
                     <given-names>G</given-names>
                  </name>
               </person-group>. <article-title>eCTD by the Numbers</article-title>. <conf-name>Presented at: DIA Electronic Submissions Conference</conf-name>; <month>October</month> 
               <day>28-29</day>, <year>2010</year>; <conf-loc>San Diego, CA</conf-loc>.</citation>
         </ref>
         <ref id="bibr31-0092861511427871">
            <label>31</label>
            <citation citation-type="book" xlink:type="simple">
               <source>Telematics Implementation Group for Electronic Submission and ICH Implementation (TIGes)</source>. <comment>eCTD Implementation Survey Report v5.0</comment>. <publisher-loc>London</publisher-loc>: <publisher-name>European Medicines Agency</publisher-name>; <year>2010</year>.</citation>
         </ref>
         <ref id="bibr32-0092861511427871">
            <label>32</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Emoto</surname>
                     <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Tamura</surname>
                     <given-names>M</given-names>
                  </name>
               </person-group>. <article-title>The implementation of eCTD in Japan</article-title>. <source>Topra</source>. <year>2011</year>;<volume>8</volume>(<issue>6</issue>):<fpage>8</fpage>–<lpage>9</lpage>.</citation>
         </ref>
         <ref id="bibr33-0092861511427871">
            <label>33</label>
            <citation citation-type="book" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Harmsen</surname>
                     <given-names>S</given-names>
                  </name>
               </person-group>. <source>Electronic Submissions: Benefits and Challenges. Guide to Drug Regulatory Affairs</source>. <publisher-loc>Aulendorf, Germany</publisher-loc>: <publisher-name>Editio Cantor Verlag</publisher-name>; <year>2008</year>.</citation>
         </ref>
         <ref id="bibr34-0092861511427871">
            <label>34</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">International Conference on Harmonisation (ICH)</collab>. <source>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use</source>. <ext-link ext-link-type="uri" xlink:href="http://www.ich.org/about/history.html" xlink:type="simple">http://www.ich.org/about/history.html</ext-link>. <comment>Accessed June 2011</comment>.</citation>
         </ref>
         <ref id="bibr35-0092861511427871">
            <label>35</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Porsche Consulting</collab>. <article-title>Arzneimittel schneller auf den Markt bringen</article-title>. <month>February</month> 
               <year>2010</year>. <ext-link ext-link-type="uri" xlink:href="http://www.chemanager-online.com/themen/dienstleistungen/arzneimittel-schneller-auf-den-markt-bringen" xlink:type="simple">http://www.chemanager-online.com/themen/dienstleistungen/arzneimittel-schneller-auf-den-markt-bringen</ext-link>. <comment>Accessed February 2010</comment>.</citation>
         </ref>
         <ref id="bibr36-0092861511427871">
            <label>36</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Hamilton</surname>
                     <given-names>W</given-names>
                  </name>
               </person-group>. <article-title>E-ticket to global harmonization</article-title>. <source>Pharm Executive</source>. <year>2002</year>;<volume>22</volume>(<issue>12</issue>):<fpage>66</fpage>–<lpage>71</lpage>.</citation>
         </ref>
         <ref id="bibr37-0092861511427871">
            <label>37</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">US Food and Drug Administration (FDA)</collab>. <article-title>Protecting and promoting your health</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/" xlink:type="simple">http://www.fda.gov/</ext-link>. <comment>Accessed June 2011</comment>.</citation>
         </ref>
         <ref id="bibr38-0092861511427871">
            <label>38</label>
            <citation citation-type="book" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Buxton</surname>
                     <given-names>T</given-names>
                  </name>
               </person-group>. <source>eCTD in the EU: Current Status &amp; Next Steps</source>. <publisher-loc>Brussels</publisher-loc>: <publisher-name>European Medicines Agency (EMA</publisher-name>); <year>2006</year>.</citation>
         </ref>
         <ref id="bibr39-0092861511427871">
            <label>39</label>
            <citation citation-type="book" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Ventura</surname>
                     <given-names>V</given-names>
                  </name>
               </person-group>. <source>CDER Update: eCTD &amp; Gateway Submissions</source>. <publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>US Food and Drug Administration</publisher-name>; <year>2010</year>.</citation>
         </ref>
         <ref id="bibr40-0092861511427871">
            <label>40</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Fritz</surname>
                     <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Minnick</surname>
                     <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Chew</surname>
                     <given-names>N</given-names>
                  </name>
               </person-group>. <article-title>Getting started with the FDA’s electronic submissions gateway</article-title>. <source>Regul Rapporteur</source>. <year>2010</year>;<volume>7</volume>(<issue>9</issue>):<fpage>4</fpage>–<lpage>6</lpage>.</citation>
         </ref>
         <ref id="bibr41-0092861511427871">
            <label>41</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">European Medicines Agency (EMA)</collab>. <source>eSubmission Gateway Project—Status Report</source>. <publisher-loc>London</publisher-loc>: <publisher-name>EMA</publisher-name>; <year>2011</year>.</citation>
         </ref>
         <ref id="bibr42-0092861511427871">
            <label>42</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Scrace</surname>
                     <given-names>S</given-names>
                  </name>
               </person-group>. <article-title>The regulatory department: an agent for knowledge sharing and process change</article-title>. <source>J Med Marketing</source>. <year>2006</year>;<volume>6</volume>(<issue>2</issue>):<fpage>126</fpage>–<lpage>130</lpage>.</citation>
         </ref>
         <ref id="bibr43-0092861511427871">
            <label>43</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Bendtsen</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Buch Leander</surname>
                     <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Hornbaek Svendsen</surname>
                     <given-names>T</given-names>
                  </name>
               </person-group>. <article-title>How to make electronic submission a business benefit</article-title>. <source>RAJ Pharma</source>. <month>September</month> 
               <year>2009</year>:<fpage>587</fpage>–<lpage>591</lpage>.</citation>
         </ref>
         <ref id="bibr44-0092861511427871">
            <label>44</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Beckloff Associates, Inc</collab>. <article-title>Evaluating the electronic submissions challenge in the pharma and biotech industries</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.cardinal.com/beckloff/documents/pdf/Electronic%20Submissions_White_Paper_030106%20BAI.pdf" xlink:type="simple">http://www.cardinal.com/beckloff/documents/pdf/Electronic%20Submissions_White_Paper_030106%20BAI.pdf</ext-link>
            </citation>
         </ref>
         <ref id="bibr45-0092861511427871">
            <label>45</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Cartwright</surname>
                     <given-names>AC</given-names>
                  </name>
               </person-group>. <article-title>The electronic common technical document: from design to submission</article-title>. <source>Int J Pharm Med</source>. <year>2006</year>;<volume>20</volume>(<issue>3</issue>):<fpage>149</fpage>–<lpage>158</lpage>.</citation>
         </ref>
         <ref id="bibr46-0092861511427871">
            <label>46</label>
            <citation citation-type="book" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Perez</surname>
                     <given-names>M</given-names>
                  </name>
               </person-group>. <article-title>The eCTD advantage</article-title>. <month>August</month> 
               <day>20</day>, <year>2009</year>. <ext-link ext-link-type="uri" xlink:href="http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/US/Common-Ground-for-eCTD/ArticleStandard/Article/detail/602040" xlink:type="simple">http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/US/Common-Ground-for-eCTD/ArticleStandard/Article/detail/602040</ext-link>. <comment>Accessed September 2009</comment>.</citation>
         </ref>
         <ref id="bibr47-0092861511427871">
            <label>47</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Pothiawala</surname>
                     <given-names>M</given-names>
                  </name>
               </person-group>. <article-title>A practical approach to e-dossier and e-document: management, tracking, publishing and submission</article-title>. <source>Regul Rapporteur</source>. <year>October 2008</year>:<fpage>19</fpage>–<lpage>21</lpage>.</citation>
         </ref>
         <ref id="bibr48-0092861511427871">
            <label>48</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">C5 Communications Ltd</collab>. <source>eCTD Survey Results 2010</source>. <ext-link ext-link-type="uri" xlink:href="http://www.c5-online.com/blog/wp-content/uploads/2010/08/eCTD-Pharma-Survey-Results.pdf" xlink:type="simple">http://www.c5-online.com/blog/wp-content/uploads/2010/08/eCTD-Pharma-Survey-Results.pdf</ext-link>
            </citation>
         </ref>
         <ref id="bibr49-0092861511427871">
            <label>49</label>
            <citation citation-type="confproc" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gens</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Scribner</surname>
                     <given-names>S.</given-names>
                  </name>
               </person-group> 
               <year>2007</year> 
               <article-title>Global EDM/eCTD survey: results of 37 bio-pharmaceutical companies</article-title>. <collab collab-type="author" xlink:type="simple">Presented at: DIA SIAC Meeting</collab>; <month>June</month> 
               <day>18-21</day>, <year>2007</year>; <conf-loc>Atlanta, GA</conf-loc>.</citation>
         </ref>
         <ref id="bibr50-0092861511427871">
            <label>50</label>
            <citation citation-type="book" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gens</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Scribner</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Brolund</surname>
                     <given-names>G</given-names>
                  </name>
               </person-group>. <source>ECM Trends: Shifting From a Content Centric to a Collaborative Centric Environment</source>. <article-title>2009 EDM/Collaboration Empirical Study of Industry Practices, Trends and Vendor Satisfaction. ILSS</article-title>; <year>2009</year>.</citation>
         </ref>
         <ref id="bibr51-0092861511427871">
            <label>51</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Liquent</surname>
                     <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Nichols</surname>
                     <given-names>J</given-names>
                  </name>
               </person-group>. <article-title>Trends im Bereich der Arzneimittelzulassung</article-title>. <source>Pharm Ind 67</source>. <year>2005</year>;<volume>11</volume>:<fpage>1248</fpage>–<lpage>1251</lpage>.</citation>
         </ref>
         <ref id="bibr52-0092861511427871">
            <label>52</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Thomson Scientific</collab>. <source>2006 Liquent Regulatory Affairs Trends Survey</source>. <month>June</month> 
               <day>19</day>, <year>2006</year>. <ext-link ext-link-type="uri" xlink:href="http://science.thomsonreuters.com/press/2006/8325640/" xlink:type="simple">http://science.thomsonreuters.com/press/2006/8325640/</ext-link>. <comment>Accessed June 2011</comment>.</citation>
         </ref>
         <ref id="bibr53-0092861511427871">
            <label>53</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Thomson Corporation</collab>. <source>2007 Liquent Regulatory Affairs Trends Survey: Summary Report</source>. <publisher-name>The Thomson Corporation</publisher-name>; <publisher-loc>Horsham, PA</publisher-loc>. <year>2007</year>.</citation>
         </ref>
         <ref id="bibr54-0092861511427871">
            <label>54</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Thomson Reuters</collab>. <source>2008 Liquent Regulatory Affairs Survey—Summary Report</source>. <publisher-name>Thomson Reuters</publisher-name>; <publisher-loc>Philadelphia, PA</publisher-loc>; <year>2008</year>.</citation>
         </ref>
         <ref id="bibr55-0092861511427871">
            <label>55</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">Liquent, Inc</collab>. <article-title>Liquent unveils the results of its regulatory affairs trends survey</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.liquent.com/media/pdf/RegTrendsSurveyResults.pdf." xlink:type="simple">http://www.liquent.com/media/pdf/RegTrendsSurveyResults.pdf</ext-link>
            </citation>
         </ref>
         <ref id="bibr56-0092861511427871">
            <label>56</label>
            <citation citation-type="web" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Lorenz</surname>
                  </name>
               </person-group>. <article-title>Regulatory professionals—eCTD survey</article-title>. <year>2008</year>. <ext-link ext-link-type="uri" xlink:href="http://www.lorenz.cc/survey" xlink:type="simple">http://www.lorenz.cc/survey</ext-link>. <comment>Accessed June 2008</comment>.</citation>
         </ref>
         <ref id="bibr57-0092861511427871">
            <label>57</label>
            <citation citation-type="web" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Pharma</surname>
                     <given-names>IQ</given-names>
                  </name>
               </person-group>. <article-title>eCTD continues rise to global prominence</article-title>. <month>June</month> 
               <day>18</day>, <year>2010</year>. <ext-link ext-link-type="uri" xlink:href="http://www.pharma-iq.com/regulatory-legal/articles/ectd-continues-rise-to-global-prominence/" xlink:type="simple">http://www.pharma-iq.com/regulatory-legal/articles/ectd-continues-rise-to-global-prominence/</ext-link>. <comment>Accessed August 11, 2010</comment>.</citation>
         </ref>
         <ref id="bibr58-0092861511427871">
            <label>58</label>
            <citation citation-type="web" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">UNICUS</collab>. <source>eCTD Readiness Survey</source>. <year>2007</year>. <ext-link ext-link-type="uri" xlink:href="http://www.keysurvey.com/survey/141953/106c/" xlink:type="simple">http://www.keysurvey.com/survey/141953/106c/</ext-link>. <comment>Accessed June 2007</comment>.</citation>
         </ref>
         <ref id="bibr59-0092861511427871">
            <label>59</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Katz</surname>
                     <given-names>NR</given-names>
                  </name>
               </person-group>. <article-title>Effective eCTD writing: five essential competencies</article-title>. <source>Global Forum</source>. <year>2011</year>;<volume>3</volume>(<issue>2</issue>):<fpage>27</fpage>–<lpage>31</lpage>.</citation>
         </ref>
      </ref-list>
   </back>
</article>